# Appendix 1 (as supplied by the authors): Descriptive meta-matrix of critical care Ebola readiness needs assessment results

This section outlines the elements/results, which must be achieved in caring for potential or confirmed cases of Ebola, with respect to critical care. The goal of the matrix is to provide information from many different sources in a manner that makes pragmatic sense to every hospital team player. The first column displays the results that we are trying to achieve. The second and third columns present recommendations/evidence to achieve the desired result, obtained from international organizations and national/provincial/local organizations, respectively. The fourth column represents a summary of our qualitative data (interviews, focus groups, walk-throughs) that will help find local solutions. The qualitative data may help other organizations (not only The Ottawa Hospital (TOH)) as they are likely to encounter very similar challenges when attempting to put in place pragmatic local solutions that are still congruent with international and national recommendations. Note that the document analysis was last updated on November 07, 2014. The proposed solutions column is not complete. Interprofessional teams at TOH are developing local solutions.

In this document, the term hospital team member (HTM) has been used in order to recognize the vital role that many individuals from various backgrounds contribute to the care of patients with potential or confirmed ebola. The interdisciplinary team of HTMs includes physicians, nurses, respiratory therapists, infection control specialists, housekeeping staff, porters, security staff, facility staff, occupational health and safety, etc A complete list of acronyms is available at the end of the matrix.

Α.	Screening before entry to ICU (or with any ICU team contact) with regards to transfer from ER, wards, OR, RR, and other
	hospitals)

			Documer	t Analysis	Qualitative Data	Proposed solutions
Result	Gap identified	Solution Implement	International Documents - WHO / CDC / Emory	National, Regional and Local - MOHLTC and TOH - CCCS - Public Health Agencies	Factors to be considered in the development and implementation of solutions	Description of solution, person responsible, timeline to implementation
A screening tool will be developed and kept up to date	N	N	CDC <sup>1</sup> - CDC has developed a screening checklist. Based on this checklist, Emory has developed protocols to screen individuals encountered in different milieus CDC <sup>2</sup> – CDC has an algorithm for returning travelers. CDC <sup>3</sup> – Screening algorithm	PHO <sup>6</sup> – The department of Public Health Ontario provides a screening tool for primary care providers. It consists of questions related to prior travel and presence of EVD symptoms. (See reference for URL link)	<ul> <li>HCPs in the ICU had the following questions:</li> <li>Which source will be used to define the criteria?</li> <li>Who maintains the tool as new data emerges?</li> <li>How often is the tool reviewed?</li> <li>A tool has been developed and is being used in the ED. Infection control has clarified that this tool is</li> </ul>	Solution – None required at this time
			available on CDC website (see reference) CDC <sup>3</sup> – "Early recognition is	TOH – Ebola triage screening tool (Nov. 7, 2014) TOH – Algorithm for assessment of potential Ebola virus diagona in	from Public Health Ontario (PHO). It is reviewed when mandated by PHO and also through internal review with infection control. There is no set	
			critical to controlling the spread of Ebola virus. Healthcare providers should evaluate the patient's	the Emergency Department (Sept 4, 2014)	time for frequency of review.	

Appendix to: Sarti SJ, Sutherland D, Robillard N, et al. Ebola preparedness: a rapid needs assessment

of critical care in a tertiary hospital. CMAJ Open 2015. DOI: 10.1503/cmajo.20150025.

Copyright © 2015 The Author(s) or their employer(s). To receive this resource in an accessible format, please contact us at cmajgroup@cmaj.ca.

		<u> </u>
	epidemiologic risk including a	
	history of travel to a country with	
	widespread Ebola virus	
	transmission or contact within the	
	necessing 21 days with a percent	
	preceding 21 days with a person	
	with Ebola while the person was	
	symptomatic."	
	EMORY <sup>4</sup> p.4-5 – Protocols have	
	been developed to screen	
	individuals They have established	
	criteria for high low and	
	intermediate rick of EVD	
	internediate lisk of LVD.	
	WHO – Screening based on	
	patient history:	
	- Any contact with someone in	
	the previous 3 weeks who	
	was ill with fever +/- bleeding	
	or who died from an	
	unexplained illness with faver	
	- Any contact with other hamily	
	members who are sick or	
	have died from a disease	
	with similar symptoms and	
	signs?	
	- Unexplained death of wild	
	animals in the area?	
	History of contact with blood	
	and body fluid of wild	
	animais (especially monkeys,	
	bats, rats, etc.)?	
	- History of visiting/exploring	
	caves or working in mines	
	infested with bats?	
	- Received a tick bite or	
	crushed a tick with their bare	
	hands?	
	Home infested with rate?	
	- Home intested with hats:	
	WHO <sup>5</sup> Cose identification and	
	detertion is becade an 2	
	detection is based on 5	
	components:	
	1- History of exposure: Within 2-	
	21 days prior to the patient's	
	onset of symptoms (within	
	the potential incubation	
	period). Exposures include	
	any blood or other body fluid	
	any block of other body hald	

			<ul> <li>including sweat, vomit, breast milk, contaminated items, animal contact (bush meat, apes or bats) and/or semen (up to 3 months after clinical recovery) from a known or suspected case of VHF (dead or alive)</li> <li>2- Detailed clinical assessment: flu-like symptoms (fever, profound weakness, arthralgia, myalgia, headache, anorexia, and hiccups followed by gastrointestinal symptoms and in late stages, minor or major bleeding and shock)</li> <li>3- Laboratory investigations</li> </ul>		
HTMs responsible for screening will always use the most current version of the tool to screen potential cases of Ebola	Y	Z		Participants questioned where the tool would be displayed and who would notify the group of the changes? Suggestions were made for screening cards, online access and posters. However, barriers with posters and cards were identified given the challenges of keeping material up to date and removing outdated material. They suggested sending emails to all employees who are expected to screen potential cases whenever the tool is updated. The ED tool is available on the TOH website. During NA however, difficulties were encountered with opening and viewing the PDF.	
All HTMs performing screening will be appropriately trained to use the most secure screening process.	Y	N	WHO' – When screening, shaking hands should be avoided, a distance of more than one meter should be maintained between interviewer and interviewee, PPE is not required when interviewing an asymptomatic patient and the above mentioned distance and provided there will be no contact with the potentially contaminated environment, perform appropriate hand hygiene with alcohol-based hand rub solutions.	<ul> <li>Currently, HTMs in critical care have not been trained on how to screen patients. Participants had the following questions:</li> <li>Who should receive training to screen?</li> <li>How are they trained to screen?</li> <li>Who will provide the training? How frequently?</li> </ul>	
All potential cases of	Ý	N N	- IT there is a suspected	Critical care HINS are currently not	

Ebola will be			case of VHF, the person screening	using a screening tool and a spot	
screened with the up			will call for help from a doctor	audit in the ICU revealed that	
to date tool and			within the facility for further	numerous cases admitted from the	
critical care HTMs will			evaluation. After further	ED and other areas had not been	
be informed of the			evaluation, contact the	screened.	
screening test result			hospital/district surveillance focal		
before any physical			person and/or district health	Critical care HTMs identified a gap in	
contact occurs.			officer. Keep the patient in the	knowing who is responsible for	
			holding room/area.	performing or confirming screening	
				at specific points of contact. Points	
				of contact were identified and	
				explored:	
				<ul> <li>ICU consults from the ED and</li> </ul>	
				OR could be screened by the	
				Care Facilitator (CF).	
				ICU consults from referring	
				hospitals could be screened by	
				both the attending MD and the	
				CF.	
				<ul> <li>With RACE there are many</li> </ul>	
				potential points of contact	
				including, ED for admitted	
				patients, ward, Rehab, PACU.	
				out patient clinics and others	
				(such as hallways and parking	
				lots). Given that some referrals	
				might not have been screened.	
				it has been suggested that	
				RACE should screen all	
				referrals.	
All patients admitted	Y	Ν		Asymptomatic infected patients from	
to ICU who are from a				high-risk area could initially be	
high-risk area or have				screen-negative but could become	
had potential contact				infectious during their stay in the	
with Ebola will receive				ICU.	
appropriate ongoing				If a patient is from a high-risk area	
screening.				has had a recent contact but is	
		1		asymptomatic, infection control will	
		1		ensure twice daily temperature	
		1		checks.	
				In order for infection control to be	
				aware of these patients the	
				screening staff would need to	
		1		contact and notity them. Currently,	
				critical care staff have not been	
				trained on how to use the tool and	
				nence would not know to notify	
				Infection control.	
		1		It was also unclear if other	
	1			symptoms need to be monitored	

			during this time.	
The screening result will be readily accessible to HTMs.	Ŷ	Ŷ	The NA identified that there was not a consistent location for the screening result. Therefore, HTMs were having difficulty finding the screening result in the chart. The recommendation was made that it be consistently placed in at the front of the chart beside the category of care document. If was further recommended to consider printing the tool on a distinct colored page.	Solution – The suggestions were brought forth to the executive committee and the screening tool is now placed with the category of care document.

## B. Response team activation

			Documen	t Analysis	Qualitative Data	Proposed solutions
Result	Gap identified	Solution Implemented	International Documents - WHO / CDC / Emory	National, Regional and Local - MOHLTC and TOH - CCCS - Public Health Agencies	Factors to be considered in the development and implementation of solutions	Description of solution, person responsible, timeline to implementation
There should be an easy and rapid way to activate a response that would not overburden HTMs who are also called upon to provide care and manage the patient.	Y	I/P	<ul> <li>WHO' – Make every effort to reduce the waiting time between initially seeing the patient and notification/referral. Develop a system to move patients quickly and reduce the time that others are exposed.</li> <li>EMORY<sup>4</sup> p.17-19 – A complete protocol of activation of their Serious Communicable Disease Unit is available (but may not be applicable to the reality of TOH's ICUs)</li> </ul>	<b>TOH</b> – Once patient has screened positive according to the TOH ER algorithm, the infectious disease physician on call, the microbiologist on call, IPAC, Ottawa Public Health, Administration on call (if off hours) CAOs must be notified by the most responsible person in ER. If Ebola testing is indicated, the ID physician is responsible for contacting the microbiologist on call before blood work (including Ebola testing) can be drawn. If the patient is admitted, and being transferred out of the ER: CAOs or CF must notify the receiving unit, and communications on call of the transfer. Housekeeping and Logistics must be notified of Ebola Droplet/contact precautions by the unit. Bed management/bed flow must be notified of this coded "C".	I deally a designated person who is not providing patient care should make contacts and phone calls. An email has been sent to ICU physicians notifying them that it is their responsibility to then notify Infectious Disease (ID)/Occupational Health/Infection Control. Need to verify if the MD must call all three or if a single call to ID is required to activate the system. Concerns were raised about delays in the provision of care if the activation process was too cumbersome (i.e. need to notify many individuals) Activation process may depend on the point of contact. In the ED for direct consult to the ICU the patient will have been screened and then the system activated by the ER screening nurse. The CF will be called from the ER and will be required to immediately inform the critical care Ebola response team.	Infection control is currently developing the process.

				For the unanticipated patient (e.g. outpatients, visitors), it is unclear how the system will be activated. It was suggested to develop a "Code E", which could utilize either a pager already in use or a dedicated pager.	
The activation will ensure that only essential personnel are notified and expected to respond.	Y	I/P	CCCS <sup>8</sup> p.13 – "The team may vary from institution but should include a senior nurse, senior physician, infection prevention and control (IPAC) officer, and employee safety officer as well as a communications officer"	HTMs identified that the composition of the team may vary depending on the point of contact and the severity of illness of the patient. While ID, infection control and occupational health and safety will always be part of the response team; other team members may vary. For example, it would be inappropriate to call the critical care Ebola response team to assess a stable patient seen in ED who is screen positive. Participants suggested that the person responsible for activating the response should follow a well- defined and simple process in order to only contact essential team member. Housekeeping and waste management wanted to ensure that they were notified early and were concerned that they could be overlooked.	Infection control is currently developing the process.
Dedicated response teams will be available to secure and manage any individual who is screen + for Ebola. The team will be immediately available regardless of patient location or time of day.	Y	I/P	CCCS <sup>8</sup> p.18 – "It is suggested hospitals, especially in the ED and Critical Care Unit, train small teams well rather than attempting to train all employees, in advanced PPE. At least 1-2 members of the advanced PPE teams should be present on each shift, to assist staff as needed, and call for the full team if necessary."	<ul> <li>At present, the composition of the Ebola response teams is unclear. Depending on the clinical situations the composition of the team may vary. Participants identified different scenarios:</li> <li>1. The critically ill patient in the ED who requires ICU care - The participants suggested that members of the critical care Ebola response team should be identified before each shift to ensure that they are readily available if called upon.</li> <li>2. The unanticipated screen + patient who is not critically ill (not meeting RACE calling criteria, for example outpatients) – Concerns have been expressed that the RACE</li> </ul>	Solution – Infection control is currently developing the process.

r				· · · · · · · · · · · · · · · · · · ·
			team should not be called to	
			manage these patients. There	
			may be a large volume of cases	
			that present with screen + who	
			are not critically ill (especially	
			with flu season approaching).	
			RACE's mandate is to care for	
			critically ill patients In addition	
			the RACE team may not always	
			be available	
		3	BACE call during the day – If a	
		Ο.	nation screens + on a RACE	
			call more staff will be required	
			to manage the nation. It was	
			suggested that the PACE MD	
			and purso would dop PPE and	
			romain with the nationt until	
			other critical care team	
		4	BACE coll during the night	
		4.	There is no ICL stoff physician	
			in house at night. Should a	
			in nouse at night. Should a	
			Patient screen + at hight during	
			a RACE call, it was suggested	
			nouse (e.g. emergency	
			physician) be called upon to	
			immediately attend to the	
			patient until the ICU staff	
			physician's arrival.	

### C. PPE

			Documen	t Analysis	Qualitative Data	Proposed solutions
Result	Gap identified	Solution Implemented	International Documents - WHO / CDC / Emory	National, Regional and Local - MOHLTC and TOH - CCCS - Public Health Agencies	Factors to be considered in the development and implementation of solutions	Description of solution, person responsible, timeline to implementation
HTMs will perform a risk assessment prior to donning PPE.	Y	I/P	WHO <sup>7</sup> – Standard precautions include point-of-care risk assessment for appropriate selection of PPE to avoid direct contact with the patient's body fluids (blood, stool, amniotic fluid, urine and respiratory secretions)	MOHLTC (Oct 30 <sup>th</sup> ) <sup>9</sup> – MOHLTC describe "Point of care risk assessment' before each interaction with a patient and/or the patient's environment to evaluate the likelihood of exposure to an infectious agent/infected source and to choose the appropriate safe work practices.	Participants suggest that the risk assessment be incorporated into the PPE training.	Solution – Have discussed adding this to the simulation training with infection control

				Health sector employers should		
				ensure that health workers are		
				Prevention and Control (IPAC)		
				recommendations from the		
				MOHI TC for EVD into their point		
				of care risk assessments.		
				including any enhancements or		
				modifications to PPE controls."		
				PHAC <sup>10</sup> – "HCWs should have		
				sufficient knowledge, skills and		
				resources to perform point of		
				contact risk assessment (PCRA)		
				petione every interaction with a		
				measures		
				Detients with summtance should be		
				Patients with symptoms should be		
				EVD and for other alternative or		
				co-existing potential		
				communicable infections (e.g.,		
				EVD, malaria, dysentery, typhoid		
				fever, tuberculosis, measles,		
				gastroenteritis)		
				Assess for travel within 21 days to		
				Ebola-affected areas, or contact		
				with an individual with onset of		
				symptoms within 21 days of travel		
				to an Ebola-affected area.		
				Assess for symptoms of $EVD$ :		
				$(101.5^{\circ}\text{E})$ and at least one of the		
				following additional symptoms:		
				malaise myalgia severe		
				headache, conjunctival injection,		
				pharyngitis, abdominal pain,		
				vomiting, diarrhea that can be		
				bloody, bleeding not related to		
				injury, unexplained hemorrhage,		
				and erythematous maculopapular		
Thoro will be a clear	V		CDC <sup>11</sup> "I loo trained observers	MOHI TC (Oct 20 <sup>th</sup> ) <sup>9</sup> p.6	In keeping with provincial standards	On Optobor 18 <sup>th</sup> the
	T	1/17	to monitor for correct PPE use and	Trained observer required to	the initial PPE training for caring for	
and doffing			adherence to protocols for donning	inspect donning and doffing of	patients with suspected or proven	directives to enhance the
appropriate PPE that			and doffing PPE, and guide	PPE to ensure inadvertent	Ebola included a fluid resistant	PPE measures used by
will protect HTMs			healthcare workers at each point	contamination of eyes, mucous	gown, one pair of gloves (two if	HTMs. Following this
while caring for			of use using a <b>checklist</b> for every	membranes, skin or clothing does	drawing blood), surgical mask,	release, ID and Infection
patients with potential			donning and doffing procedure"	not occur. As possible, the	goggles and a face shield. Later	control sourced equipment
or confirmed Ebola.				observer should watch HCW	neck and boot covers were added.	and rapidly developed

11	1		
CDC'' – "The trained observer is a	activities in the patient room."	Participants felt that this equipment	curriculum on PPE donning
dedicated individual with the sole		and process was inadequate and did	and doffing with the new
responsibility of ensuring	PHAC <sup>10</sup> – "PPE should be	not offer sufficient protection. In	equipment. Still to need to
adherence to the entire donning	provided outside the patient's	addition, participants identified errors	determine if PAPR
and doffing process"	room or in the entercom	in the videos that were provided to	equipment will be acquired
31	room of in the anteroom.	enhance training and the quality of	and if so the process Also
<b>CDC</b> <sup>11</sup> – Ensure adequate time for		the face-to-face training was also	need to discuss addition of
donning and doffing of PPE by	Consider assignment of trained	questioned Eurthermore many	an aprop
HCP without interruptions and	individual to monitor appropriate	participants described feeling that	un upron.
distractions	selection and application removal	their concerns were not being	
uistractions		chell concerns were not being	
CDC <sup>11</sup> Ouidalines for required	and disposal of PPE, to observe	the infection control staff which	
CDC – Guidelines for required	and ensure HCW not	the infection control staff, which	
PPE for trained observers if they	contaminating self and to monitor	contributed to a lack of trust. In	
enter the contaminated area	entry to room (i.e. limit entry to	contrast, infection control staff	
(anteroom) to help with the doffing	only essential HCWs)	described experiencing much	
of HCP's PPE. (Refer to web site)	The use of few each area of DDE (a. a.	anxiety and worry about providing	
44	The need for enhanced PPE (e.g.	the education during this time,	
CDC''– Stepwise guidelines for	double gloving, leg and shoe	fearing that they would not be well	
donning and doffing equipment	coverings), is determined by	received.	
available on CDC website	assessing the risk of heavy		
	exposure to blood and body	HTMs wanted to ensure that proper	
EMORY <sup>4</sup> p.40 – See Appendix 6	fluida). Note: In late stages of	procedures were in place for	
(SCDU PPE: Donning and Doffing	nuids). Note. In late stages of	decontamination and to remove	
Protocols)	EVD, there may be copious	bodily fluid on their PPE before	
Very detailed instructions on how	secretions and excretions.	doffing. For example, use of Clorox	
to don and doff PPE.		prior to exiting the patient room to	
	Gloves	wipe of any soiled surfaces.	
CDC <sup>11</sup> – Recommended	Chould fit acouroly over	. ,	
equipment:	<ul> <li>Should fit securely over</li> </ul>	A new training program was	
1) Respiratory protection: Powered	gown cun and should be	developed and implemented.	
air-purifying respirator (PAPR) or	worn to enter the patient	Interviews with HTMs following their	
N95 respirator	room	training session identified that	
2) Gowns: "Single-use	<ul> <li>Should be removed and</li> </ul>	overall they felt the educational	
(disposable) fluid-resistant or	discarded into a no-	session went well and the equipment	
impermeable gown that extends to	touch waste receptacle	and process were much improved	
at least mid-calf or coverall without	and HH should be	HTMs were impressed with the	
integrated bood. Coveralls with or	performed on exit from	speed with which the program had	
without integrated socks are	the patient room	been nut together and also	
accentable"	Gowns:	described a positive learning	
3) Gloves: two pairs minimum /	A long-sleeved cuffed	environment: the infection control	
nitrile	fluid-resistant or	professionals being much more	
A) Shaq qoyora: "Single yee	impormosplo gown	professionals being much more	
(disposable) fluid resistant or	should be put on prior to	their commonts and suggestions	
(uisposable), liulu-resistant of	should be put on phot to	their continients and suggestions.	
avtend to at least mid calf or		Questions still remained about	
single use (dispessible) abox	<ul> <li>Reusable gowns should</li> </ul>	various apporte of doffing	
single-use (uisposable) single	be removed and placed	Concerns were expressed about the	
fluid registent or importantle	into a no-touch used	difficulty with removing the headed	
	linen receptacle	annoully with removing the housed	
shoe covers are acceptable only if	immediately after use	coverails and the need for more	
they will be used in combination	and HH should be	practice required to attain	

<ul> <li>with a coverall with integrated socks"</li> <li>5) <u>Apron</u>: "Single-use (disposable), fluid-resistant or impermeable apron that covers the torso to the level of the mid-calf should be used if Ebola patients have vomiting or diarrhea."</li> <li>WHO<sup>5</sup> p. 46-47 – HCW will use standard precautions consistently when providing care to all patients. Regardless of their diagnosis. Their rigorous implementation is crucial for the control of outbreak situations. This is key since early symptoms are non-specific.</li> <li>WHO<sup>7</sup> – The dressing and undressing of PPE should be supervised by another trained member of the team.</li> <li>WHO p.52-58<sup>5</sup>p.6<sup>7</sup> – Perform hand hygiene: with alcohol-based hand rub or soap and running water, especially if the hands are visibly soiled (technique Annex 3)</li> <li>Before donning gloves and wearing PPE on entry to the isolation room</li> <li>Before any procedure</li> <li>After any exposure (risk or actual) to patient's body fluids or blood</li> <li>After removal of PPE, leaving the care area</li> <li>WHO<sup>5</sup> – Glove change between patients: disinfect using an alcohol based hand rub, the outer gloves before removing them safely then disinfect the inner gloves before putting on another fresh outer pair</li> </ul>	<ul> <li>performed before leaving the patient room.</li> <li>Disposable gowns should be discarded into a no-touch waste receptacle immediately after use and HH should be performed before leaving the patient room.</li> <li>Facial Protection (i.e., masks and eye protection, or mask and face shield) should be worn on entry to the room.</li> <li>Note: Masks with visors are not suitable; face shields should be long enough to prevent splashing underneath; eye glasses are not suitable eye protection."</li> <li>TOH – Donning and Doffing sequence of PPE (Oct 22, 2014): A spotter must be present at all times of donning and doffing PPE</li> <li>TOH – Personal protective equipment for Ebola Virus Disease Narrative Checklist: Putting on PPE (Nov. 5, 2014)</li> <li>TOH – Personal protective equipment for Ebola Virus Disease Narrative Checklist: Removing PPE (Nov. 5, 2014)</li> </ul>	proficiency. Suggestions were also made to have dedicated footwear and an apron to be removed in the patient room before entering the anteroom. The apron was noted to be particularly important when caring for critically ill patients. At the time of the investigation, it was recommended by the MOHLTC that HTMs wear a PAPR suit when performing aerosol-generating procedures. This equipment had not been acquired and participants were unclear whether the PAPR suit should only be used with intubation or also with other aerosol generating procedures.	

	protection (face shield, goggles),		
	should be taken off as late as		
	possible during the PPE removal		
	process preferably at the end to		
	process, preferably at the end, to		
	prevent inadvertent exposure of		
	the mucous membranes.		
	WHO <sup>5</sup> p. 52-58 – PPE should be		
	put on in dedicated changing		
	zones, before entering the		
	isolation rooms/areas.		
	WHO <sup>7</sup> p. 7-8 – Recommended		
	PPE includes (sequence in Annex		
	2):		
	Scrub suit: should be put on in the		
	changing room.		
	Hand hygiene and double nitrile		
	gloves (Annex 3): Hands are		
	known to transmit pathogens to		
	the body or face and to other		
	individuals Preferably the outer		
	glove should have a long cuff		
	going over the gown and reaching		
	well above the wrist ideally to the		
	mid-forearm. The inner glove		
	should be worn under the cuff of		
	the gown/coverall		
	Disposable gowns or coveralls		
	with apron in addition to surgical		
	scrubs: should be fluid resistant		
	(blood and body fluids)		
	Eace cover including fluid-resistant		
	medical/surgical mask and face		
	shield or goggles: to protect		
	mucosa of mouth nose and eves		
	the fluid-resistant masks should		
	not collapse at the mouth		
	Protective waterproof footwear:		
	hoots are proferred over closed		
	shoos, non slip impormashla shoo		
	shoes, non-silp impermeable shoe		
	Head cover should cover the		
	head and pack concrete form the		
	neau anu neck, separate form the		
	gown of coverall nowever if not		
	available, a coverall with a nood		
	can be worn after eye, nose and		
	mouth protection are worn.		

			<u>Fluid-resistant particulate</u> <u>respirator:</u> use when doing procedures that generate aerosols of body fluids by cough or nebulized medications (diagnostic sputum inductions, bronchoscopy, airway suctioning, endotracheal intubation, PPV via face mask)			
All equipment used in the process of donning and doffing will be available and easily accessible.	Y	I/P		<b>TOH</b> – Checklist to determine environmental readiness for an Ebola patient (Oct. 31, 2014) Hallway: Identify Ebola cart location, have a log list ready to post, have stool in the hallway for HCP to sit when putting on PPE, confirm PPE sequencing checklist is located in the hallway Anteroom: post PPE sequencing checklist, cover computer with plastic bag, identify soiled and clean floor space in the anteroom: using tape and have safe trial doffing in the anteroom to confirm location of soiled area, have garbage bin lined with red bag to dispose of PPE, and test location to make sure its in arms length for the HCP, ensure mirror in the anteroom is in place to allow for ease of visualization of doffing PPE, identify location for the 3 bags to hold the clean gloves, ensure Clorox wipes are easily available for all steps in the sequencing of doffing , have stool/chair in the anteroom (soiled area) to allow for sitting during suit removal, ensure scissors are in place in the anteroom.	<ul> <li>Participants wanted clarification of the following:</li> <li>Where is the PPE equipment kept? ED, ICU, RACE, ward?</li> <li>Who stocks the equipment and how often is it checked / verified?</li> <li>Where to store equipment on the RACE cart?</li> <li>It was suggested that RACE staff select appropriately sized and labeled PPE at the start of their shift and add individually packaged PPE with a checklist on the RACE cart.</li> </ul>	Solution – equipment is now available in clear locations in the ICU and ED. There is no equipment on the RACE cart. Some sizes are not available yet and need to determine if will have the PAPR suit and aprons
HTMs will be proficient with the donning and doffing of PPE before any patient encounter or entering an Ebola precaution room.	Y	I/P	CDC <sup>11</sup> – "Train healthcare workers on all PPE recommended in the facility's protocols. Healthcare workers should practice donning and doffing procedures and must demonstrate during the training process competency through testing and assessment before caring for Ebola patients"	CCCS <sup>8</sup> p.22 – "specific training is required for those who are going to act as a safety officer ('Buddy') to direct the donning and doffing of PPE."	Participants emphasized the importance and willingness to participate in ongoing training and suggestions were made to develop a quality assurance process whereby HTMs would be required to demonstrate their competency in order to obtain certification.	Solution – Simulation training has started at the simulation center. Plans are being developed for ongoing training

			<ul> <li>CDC<sup>11</sup> – Documentation of Training for each HCP</li> <li>CDC<sup>11</sup> – "Training should be available in formats accessible to individuals with disabilities or limited English proficiency"</li> <li>WHO<sup>5</sup> – A thorough mandatory training on the use of PPE followed by mentoring for all users before engaging in any clinical care is considered fundamental for preventing infection among HCWs.</li> <li>WHO<sup>5</sup> – PPE for waste management is the same as the PPE used for patient care except that the employee will wear heavy duty/rubber gloves when handling infectious waste (e.g. solid waste or any secretion or excretion with visible blood). Goggles provide greater protection than visors from splashes that may come from below when pouring liquid waste from a bucket. Avoid splashing.</li> </ul>		HTMs emphasized the importance of donning PPE prior to any physical contact with the patient, even if the patient is at risk of imminent death. This approach, where personal protection takes precedence over patient rescue, was identified by some HTMs as a potential source of stress. Being unable to assist the patient in distress will not only cause anguish but might also lead to error with donning PPE if performed hastily. HTMs suggested cueing one another to take the time to follow the proper procedures.	
when the clinical scenario changes and they must escalate their level of PPE	Y	N	EMORY p. 38 – See Appendix 5 (PPE Guidance Matrix for PPE). Describes the different equipment required according to the level of suspicion of EVD + presence of symptoms and according to the responsibility of the HCW (e.g., nursing, MD, waste management,)	MOHLIC (Oct 30 <sup>-0</sup> ) <sup>o</sup> p.5,7-8 – Recommended PPE for HCW conducting screening/triage in the ED: When protected by a suitable structural barrier HCWs conducting screening/triage must have ready access to the following PPE: 1) A fit-tested N95 respirator 2) Full face shield 3) Gloves with extended cuffs4) Fluid-resistant gown Recommended PPE when coming in contact with suspected or confirmed cases of Ebola: 1) Fit tested, seal-checked N95	Participants identified that during a patient encounter the situation may change and the HTM may need to escalate their level of PPE (i.e., to don a PAPR suit). It was suggested that this be incorporated into the PPE education.	

	respirator 2) Full face shield (+/- goggles) 3) Double gloves 4) Full body barrier protection (see document for description of equipment) 5) Single use impermeable apron <b>Recommended PPE when</b> <b>performing aerosol-generating</b> <b>procedures:</b> 1) Powered air-purifying respirator (PAPR) with a hood or a fit-tested, seal-checked N95 respirator with a full face shield 2) Double gloves (one under and one over cuff) 3) Full body barrier protection – the aim should be no exposure of skin, which for example can be achieved by the use of the following components: - Single use (disposable) impermeable gown that extends to at least mid-calf, single-use (disposable) impermeable boot covers that extend to at least mid- calf, and single-use (disposable) surgical hood OR - Single use (disposable) impermeable coveralls - with an integrated or separate impermeable boot covers 4) Single-use (disposable) impermeable boot covers 4) Single-use (disposable)	
	integrated or separate impermeable boot covers 4) Single-use (disposable) impermeable apron may be selected by the HCW based on the risk of exposure to blood or other body fluids	

## D. Managing Post-Exposure to Virus through Body Fluids

			Documen	t Analysis	Qualitative Data	Proposed solutions
Result	Gap identified	Solution Implemented	International Documents - WHO / CDC / Emory	National, Regional and Local - MOHLTC and TOH - CCCS - Public Health Agencies	Factors to be considered in the development and implementation of solutions	Description of solution, person responsible, timeline to implementation
There will be clear definition of an unprotected exposure	N	N	CDC <sup>12</sup> – Definition = "Not wearing recommended PPE at the time of patient contact or through direct contact to blood or body fluids" WHO <sup>5</sup> p. 41 – The main route for acquisition of filovirus infection is through contact of infected blood or other body fluids with the mucous membranes of the mouth, nose and eyes. Transmission can occur through direct contact with these body fluids, or through contact with fomites (i.e. touching inanimate objects), such as the floor, utensils, and bed linens that have recently been contaminated with infected body fluids. Transmission through intact skin has not been documented. Infection can be transmitted through penetrating injuries of the skin, such as needle-stick injuries. WHO <sup>7</sup> p. 13 – Percutaneous or muco-cutaneous exposure to blood, body fluids, secretions or excretions from a patient with suspected or confirmed VHF.		HTMs are aware of the definition of unprotected exposure.	Solution – None required at this time
HTMs will recognize when exposure has occurred	Y	I/P	CDC'' – "Use trained observers to monitor for correct PPE use and adherence to protocols for donning and doffing PPE, and guide healthcare workers at each point of use using a <b>checklist</b> for every donning and doffing procedure"		A buddy system was of high importance to all team members. Participants identified that they have never performed the role of the buddy and would require training. Participants raised concerns about the effectiveness of the buddy	Solution – Training is in progress.

Appendix to: Sarti SJ, Sutherland D, Robillard N, et al. Ebola preparedness: a rapid needs assessment

of critical care in a tertiary hospital. *CMAJ Open* 2015. DOI: 10.1503/cmajo.20150025. Copyright © 2015 8872147 Canada Inc. or its licensors

		WHO <sup>7</sup> – The dressing and undressing of PPE should be supervised by another trained member of the team.		system when multiple HTMs are active in the patient's room (i.e., HTMs outnumbering buddies).	
HTMs will be proficient in taking immediate actions if exposure to body fluids occurs		<ul> <li>CDC <sup>12</sup> – 1) stop working 2) wash skin surfaces with soap and water 3) contact occupational health/supervisor (post exposure protocol for other pathogens)</li> <li>EMORY<sup>4</sup> p.45 – (Appendix 6: Additional Protocols – Needle stick or cut): <ul> <li>"Quickly sanitize gloves.</li> <li>Remove inner and outer gloves and expose wound.</li> <li>Express wound.</li> <li>Flush wound with water for five minutes.</li> <li>Cover wound by donning glove.</li> <li>Doff per patient room SOP.</li> <li>Report for medical assessment.</li> <li>Log and report incident and notify occupational injury management."</li> </ul> </li> <li>WHO<sup>7</sup> p. 13 – Persons including HCWs with exposure (as defined above), should immediately and safely stop any current tasks, leave the patient care area, and safely remove PPE. Remove PPE carefully according to the steps outlined in PPE. Immediately after leaving the patient care area, wash the affected skin surfaces or other percutaneous injury site with soap and water. Accordingly, irrigate mucous membranes (conjunctiva) with copious amounts of water or an eyewash solution, and not with chlorine solutions or other disinfectants.</li> </ul>	<ul> <li>MOHLTC (Oct 30")<sup>o</sup> p.10         <ol> <li>"Stop working immediately.</li> <li>Wash any affected skin surfaces with soap and water; for mucous membrane splashes (e.g., conjunctiva) irrigate with copious amounts of water or eyewash solution"</li> <li>"Immediately contact a supervisor and the OHS team for assessment and post-exposure management for blood-borne pathogens (e.g., hepatitis B virus, hepatitis C virus, and HIV) as per usual organizational policy"</li> </ol> </li> <li>PHAC<sup>10</sup> – "First aid should be performed immediately if there has been exposure to blood or body fluids.</li> <li>The exposure should be reported immediately to employer and immediate medical attention should be obtained.</li> <li>The site of a percutaneous injury should be thoroughly rinsed with running water, and any wound should be gently cleansed with soap and water.</li> <li>Mucous membranes of the eyes, nose or mouth should be flushed with running water if contaminated with blood, body fluids, secretions or excretions.</li> <li>Non-intact skin should be rinsed thoroughly with running water if contaminated with blood, body fluids, secretions or excretions.</li> </ul>	<ul> <li>Participants raised numerous concerns with the decontamination procedures:</li> <li>Should the HTM stay in the room?</li> <li>How to perform decontamination without worsening the situation?</li> <li>How to irrigate? Water could go down gown or suit or over the floor?</li> <li>Is there need for an absorbent barrier to be placed on the floor?</li> <li>Should they call a colleague to don and assist, which takes significant time?</li> <li>Is there a sink? Where is it? Can fluid go down the sink?</li> <li>Suggestion made review Emory protocol and adapt to local context and environment.</li> </ul>	Occupational health and safety noted that they will organize a meeting with infection control and key stakeholders to walk-through the step in our context and adapt current TOH protocols. Will include review of the Emory protocols. Then simulation and education

				stick injury		
				Stor injury		
There will be appropriate facilities available to decontaminate HTMs if exposed	Y	N	CDC <sup>11</sup> – Establish a facility exposure management plan that addresses decontamination and follow-up of an affected healthcare worker in case of any unprotected exposure. Training on this plan and follow-up should be part of the healthcare worker training WHO <sup>5</sup> – Immediately report the incident to the local coordinator. This is a time-sensitive task and should be performed as soon as the HCW leaves the patient care unit.		Procedure may require a shower and currently there is not one readily available. Interim solution may include going downstairs to use the shower in the locker room, however this is not ideal given the distance needed to travel and risk of contaminating other surfaces. Also, it was identified by facility staff that the men's shower currently has a leak into the basement, which could risk contaminating other surfaces. Consider adding a shower beside the ICU room dedicated to caring for these patients (especially given that this center is a dedicated Ebola/VHF site). There is a potential space outside the anteroom to add a shower. One participant also questioned if an eyewash station with a foot peddle is required.	
HTMs exposed to bodily fluids will be informed of the procedure to follow over the ensuing days	Y	N	<ul> <li>CDC <sup>12</sup></li> <li>A - Development of sudden onset fever, muscle pain, weakness, vomiting, diarrhea or any signs of hemorrhage after unprotected exposure: <ol> <li>Not report or stop working</li> <li>Notify supervisor</li> <li>Seek medical assessment and testing</li> <li>Notify regional health services</li> <li>Comply with work exclusion until no longer infectious</li> </ol> </li> <li>B - Asymptomatic HCP with unprotected exposure <ol> <li>Medical evaluation and follow-up ad 21 days after last exposure</li> <li>Temperature taking twice daily</li> <li>C – Asymptomatic personnel with protected exposure</li> <li>Develop policies to ensure twice daily checks (symptoms and fever)</li> </ol> </li> </ul>	MOHLTC (Oct 30 <sup>th</sup> ) <sup>9</sup> p.10 – For asymptomatic HCWs who had an unprotected exposure to a patient with EVD: - Should receive medical assessment and check temperature twice daily and monitor for symptoms of EVD - Report fever greater than 38 or other symptoms - Public health unit should advise on any restrictions regarding activities and travel for 21 days from the HCW's last exposure - No patient contact for 21 days from last exposure. HCWs who have been caring for or exposed to EVD patients, and subsequently develop fever, should: - Not report to work or immediately stop working - Notify their supervisor and Occupational Health Department - Saek promet medical evaluation	Occupational health and safety is available 24 hours a day for Ebola related issues. There is policy in place, however not all of the HTMs concerns are addressed in the policy. HTMs were unclear about what to do following unprotected exposure with regards to monitoring, work leave, contact with family, etc. Questions raised included: Who will do the monitoring? Will it be documented? If so, who calls and how will it be documented? What will be monitored? Only fever or other symptoms? The question was raised: what do we inform HTMs about their families? Given that it is deemed unsafe to manage patients once exposed, HTMs expressed concerns about the safety of returning home to their families. HTMs were also	

	1	1	"aublic bealth actions" to tal.	and to dive an aliginally indiants	menopeling a metional with Thete areas	
			according to the exposure	- Comply with work exclusion as	in the absence of unprotected	
	1	1	category (high risk some risk low	per their OHS/local public health	exposure	
			risk and no risk) and the presence	unit (PHU) until they are deemed	exposure.	
	1	1	or absence of symptoms	no longer infectious to others	If HTMs develop symptoms they	
					raised questions about what do?	
			WHO <sup>7</sup> – Exposed persons should	TOH - has a policy "Monitoring	HTMs clearly understand the need	
	1	1	be medically evaluated including	and Management of Health Care	to report the symptoms and be	
			for other potential exposures (e.g.	Providers Potentially Exposed to	assessed. However, the exact steps	
			HIV, HCV) and receive follow-up	Ebola Virus Disease	to be taken need clarification	
			care, including fever monitoring		including where to go (the ED or	
			twice daily for 21 days after the		another location) and what will happen to their family?	
			incident. Immediate consultation			
			with an expert in infectious		A policy is available at TOH but it	
			diseases is recommended for any		does not address all of HTMs	
			exposed person who develops		concerns/questions. Suggestions	
			fever within 21 days of exposure		were made to create an information	
			iever within 21 days of exposule.		pamphlet.	
			HCWs suspected of being infected			
			should be cared for/isolated and			
			the same recommendations			
			autipad in this desumant must be			
			outlined in this document must be			
			applied until a negative diagnosis			
			is confirmed.			
			Contact tracing and follow up of			
			family friends co-workers and			
			other patients who may have			
			been exposed to the Ebola virus			
			through close contact with the			
			infected HCW is essential.			
All HTMs who help	Y	Ν	EMORY <sup>4</sup> p.9 – "All employees	MOHLTC (Oct 30 <sup>th</sup> ) <sup>9</sup> p.10 –	Participants were concerned that a	
manage a patient with			involved in the direct care of a	For asymptomatic HCWs who had	missed exposure could occur and	
Ebola will be			patient with EVD will be monitored	protected exposure (e.g., wearing	wanted HTMs to be appropriately	
monitored, even if			for 21 days after the last direct	recommended PPE at all times) to	monitored. HIMs were unclear of	
unprotected oxposure			EVD patient" (see appondices #1	a confirmed case of EVD and/of	the monitoring process.	
unprotected exposure			and #2)	- Monitor for 21 days from last		
			EMORY <sup>4</sup> p.25 – "All employees			
			involved in direct or indirect patient			
			care or waste management are			
			also required to complete			
			symptom surveys twice daily" (see			
			appendix 2)			
			EMORV <sup>4</sup> n 29 - "Staff are also			
				1	1	

	trained to self-monitor and record twice daily temperatures for a period of 21 days after the last		
	exposure to EVD."		

## E. Patient Placement, Room Set up, Logging and Signage

			Documen	t Analysis	Qualitative Data	Proposed solutions
Result	Gap identified	Solution Implemented	International Documents - WHO / CDC / Emory	National, Regional and Local - MOHLTC and TOH - CCCS - Public Health Agencies	Factors to be considered in the development and implementation of solutions	Description of solution, person responsible, timeline to implementation
The most suitable rooms to manage patients with suspected or proven Ebola will be selected and then redesigned and equipped if required.	Y	Y	CDC <sup>11</sup> – Single room / closed door / private bathroom CDC <sup>11</sup> – "Designate spaces so that PPE can be donned and doffed in separate areas" CDC <sup>14</sup> – Inpatient care of patients with Ebola should be provided in a hospital with capacity to perform continuous renal replacement therapy (CRRT) WHO <sup>5</sup> p.16, 21 – Isolate suspected or confirmed hemorrhagic fever cases in single isolation rooms with an adjoining dedicated toilet or latrine, showers, sink equipped with running water, soap, and single-use towels, alcohol based hand rub dispensers, stocks of PPE, stocks of medicines, good ventilation, screened windows, doors closed. Keep suspected and confirmed cases separate. If an isolated room is not available, cohort the patients in specific confined areas and ensure that there is at least 1-meter distance between patient beds. WHO <sup>5</sup> – Patient charts and records should be kept outside the isolation rooms/areas.	CCCS" – Considerations for potential areas for EBV care: - "Single patient room with private bathroom, door and anteroom. <u>Negative pressure isolation is only essential if aerosol generating procedures are to be conducted"</u> -"Ability to dispose of body fluids within the patient's room" -"Infrastructure for patient to <u>communicate to staff/visitors</u> <u>outside</u> of the room" -"Ability to restrict access to the area as well as to the patient's room" -"Ability to provide dedicated patient care equipment" -"Ability to provide critical care without having to move the patient should he/she deteriorate" (i.e., need for suction, monitors, sink [dialysis], electrical outlets [with emergency power supply], medical gas (O2 & other) connections, Space for life support equipment [ventilator, dialysis machine, pumps]) -Overhead hoists if possible (reduce contact when moving patient) (See CCCS document for detailed description of other considerations) -"Close access to elevators or	<ul> <li>Participants expressed concerns that the room designated as the Ebola room in the ICU was less than ideal.</li> <li>Furthermore, it was unclear how to adapt the room given its physical layout.</li> <li>Questions raised by participants included: <ul> <li>Is there sufficient space outside of the room to stock equipment?</li> <li>How will visitors be affected by the current room placement?</li> <li>What equipment should be kept in the patient room, anteroom and outside the anteroom?</li> <li>How to define and clearly identify spaces that should be considered contaminated versus those that are clean?</li> <li>How to ensure that the room set up does not negatively impact patient care?</li> </ul> </li> </ul>	Solution – Iterative data was gathered from HTMs to identify criteria for selection of an Ebola patient room. These criteria were applied in the selection of a new Ebola room. Subsequently numerous interviews and walk-throughs with HTMs were carried out to develop a contextualized guide for room setup and actions were taken to re- design and equip the room.

r			
	WHO' p. 6 – Ideally, an isolation	diagnostic suites to minimize	
	area should already be available	transportation times"	
	to admit patients requiring		
	isolation. If an isolation area is not		
	available or if advance	MOHI TC (Oct 20 <sup>th</sup> ) <sup>9</sup> n.6 "Eor	
	preparations have not been done,	designated hospitals providing	
	and VHF is suspected,	care to a confirmed case, the	
	immediately identify and set aside	patient must be placed in an AIIR	
	a single room	with negative pressure, an	
	a onigio roonn	antoroom and a dodicated	
		washroom. »	
		MOHLTC (Oct 30 <sup>th</sup> ) <sup>9</sup> p.6 – "The	
		patient care area must be	
		monitored at all times At	
		monitored at an times. At	
		minimum, nospitais must log the	
		movement of all HCWs in and out	
		of the patient's room."	
		MOHLTC (Oct $30^{\text{th}})^9$ p 7 –	
		"Hospitals must onsure that space	
		and levent elleve for elect	
		and layout allow for clear	
		separation between clean and	
		potentially contaminated areas"	
		PHAC <sup>10</sup> – "Place suspected or	
		confirmed EVD natient in single	
		room with dedicated tailet or	
		commode; keep the door closed.	
		Advise the patient to perform HH	
		and adhere to respiratory hygiene	
		Place isolation sign on door	
		Only essential personnel with	
		appropriate PPE to optor: door	
		appropriate FFL to effect, 0001	
		should remain closed.	
		Maintain a log of all persons	
		entering room; only essential	
		personnel to enter.	
		Consider assignment of trained	
		individual to monitor appropriate	
		selection application removal and	
		diapopol of DDE to syste	
		contamination of the HCvv, and to	
		monitor entry to room (i.e., limit	
		entry to only essential HCWs).	
		Patients with symptoms	
		compatible with airborne infections	
		(i.e., measles, tuberculosis) -as	
		indicated by PCRA should be	
		placed in an airbarna infaction	
		placed in an alloome injection	

ГГ						
				isolation room (AIIR) as soon as possible. Patients with a diarrheal illness should be placed into a single examining room with dedicated toilet or commode whenever possible and as soon as possible. The patient should be directed to perform HH after using the toilet." <b>TOH</b> – Patient room log (suspected or confirmed EVD) Aug, 2014 <b>TOH</b> – Remove unnecessary items and only necessary equipment, supplies, remains in the room; ensure red pails are in the room prior to occupancy. Ensure Ebola cart is located outside the room <b>TOH</b> – Ebola designated rooms (Oct 31, 2014)		
Appropriate signage will be posted in the event of a suspected or confirmed case.	Y	N	CDC <sup>11</sup> – Signage to identify key areas: (1) PPE storage and donning area, (2) Patient room and (3) PPE removal area Further signage for reminders: (1) clean vs soiled areas, (2) wait for trained observer, (3) remind to slow and deliberate nature of PPE removal and (4) remind HCP to disinfect gloved hands between steps of doffing		Participants described the procedure for notifying HTMs of the required precautions, which consisted of placing three standard posters (airborne, droplet and contact) on the entrance. They felt that a special poster should be developed to identify the special precautions for these patients. Participants further stated that the poster(s) would have to be strategically positioned to prevent any staff from accidentally entering the room.	
Entries and exists of	Ν	Ν	CDC <sup>11</sup> – Monitor isolation area.	TOH – has a document available	HTMs were aware that all persons	
will be logged.			the room		A document is available to log entries and exits	
			WHO <sup>5</sup> p. 46 – Maintain a log of persons entering the room.			

## F. Intra-hospital Patient Movement

			Documen	t Analysis	Qualitative Data	Proposed solutions
Result	Gap identified	Solution Implement	International Documents - WHO / CDC / Emory	National, Regional and Local - MOHLTC and TOH - CCCS - Public Health Agencies	Factors to be considered in the development and implementation of solutions	Description of solution, person responsible, timeline to implementation
HTMs will be able to determine the most suitable room placement for any patient with suspected or confirmed Ebola	Y	N		TOH – Intrahospital transfers should be restricted unless the patient needs increased level of care (critical care) TOH – Ebola designated rooms (Oct 31, 2014)	Beds have been clearly designated in the hospital in the ER, medicine, OB GYN and ICU. Participants indicated that in certain circumstances it is unclear where the patient should be transported. For example, they noted that not all patients who are screen positive on a RACE call should go to the ICU. They further suggested that an algorithm be developed to assist their decision-making.	
Measures will be in place to optimize early recognition of patient deterioration in order to ensure safe transfer	Y	I/P			Resuscitation of a patient on the ward will be very challenging and participants agreed that it was essential to transport patients early before they deteriorate on the ward. Suggestions were made that all patients with confirmed Ebola who are admitted to the ward should be an automatic RACE consult. The RACE team would see the patient once or twice daily to assess their clinical status and vital signs (not required to enter room for assessment) in order to optimize early recognition.	To be discussed at next RACE meeting
The transport process will be clearly defined and will only include essential staff	Y	I/P	WHO <sup>7</sup> – Only take a patient out of their room/care area if they are free of virus, or for essential, life- saving tests.	MOHLTC (Oct 30 <sup>th</sup> ) <sup>9</sup> p.9-10 – Internal transfer only for <u>essential</u> <u>medical procedures</u> that cannot be performed in the patient's room. MOHLTC (Oct 30 <sup>th</sup> ) <sup>9</sup> p.9-10 – Transport process: -Patient must wear a mask -Exclude all patients and visitors from transport pathway -Ensure new room is ready. -Transport team needs to wear full PPE. It must be discarded as they leave the initial room. New PPE	<ul> <li>Participants expressed concerns that no procedures were in place to ensure the safe transport of these patients to and from the ICU.</li> <li>Transport from various areas of the hospital added layers of complexity:</li> <li>ED to ICU – numerous issues were identified including: the cluttered pathway; potential for people to get in the way; roles and responsibilities of the staff both inside and outside of the ED Ebola room; interventions required in advance of</li> </ul>	ED to ICU - Many WTs performed with key stakeholders to define each step. Added a readiness assessment before entering room and transporting – minimize number of people in and to body fluid management strategy See Appendix for preliminary walk-through procedure Ward to ICU - 1 <sup>st</sup> walk- through performed and gaps

			must be put on before booding in	transport (a g intubation NC	identified Need to do many
			the hellway	Liansport (e.g. intubation, NG,	
			Ine naliway.	Foley), identification and	more.
			-For diagnostic tests, the receiving	cleaning of contaminated	<b>N N N N N N N N N N</b>
			unit must be aware of the patient's	surfaces and spills during	No walk-throughs yet to
			arrival. Use the most direct route.	transport; minimizing staff but	imaging or to morgue
			Test immediately. Clean and	still ensuring enough for safe	
			decontaminate diagnostic	transport and observation of	
			equipment after procedure.	the team.	
				<ul> <li>Ward to ICU – given the</li> </ul>	
				location and space available,	
				participants felt that it would be	
				very difficult to avoid	
				contaminating surfaces during	
				transport. Participants	
				identified that using the	
				elevator was introducing	
				additional risk in the transport	
				process.	
				Participants identified that transport	
				ef ether groop such as diagnostic	
				of other areas such as diagnostic	
				imaging and the morgue would need	
				to be examined more closely.	
				It was recognized that HTMs in the	
				patient room were contaminated and	
				needed to doff PPE before transport.	
				However, participants were unclear	
				of the process during transport	
				especially when leaving a	
				contaminated area.	
				<ul> <li>Should the transport team enter</li> </ul>	
				the patient room?	
				<ul> <li>If so, who manages the patient</li> </ul>	
				while the team is doffing then	
				donning new PPE?	
				<ul> <li>Where is the patient during that</li> </ul>	
				period of time?	
				<ul> <li>Is it preferable for the transport</li> </ul>	
				team not to enter the room?	
There will be a clear	Y	N		Participants wanted to know who	
and simple process to				would be responsible for assembling	
assemble the team				the team. Participants also wanted	
required to transport				to have clear information on how to	
the patient. Team				reach the necessary transport team	
members involved in				members. There were concerns that	
the transport will be				key members may not be called or	
readily available at all				may not be immediately available -	
times.				such as housekeeping and security	
				staff. Furthermore, they expressed	

				concern that fully trained individuals may not be reachable or readily available. Housekeeping and waste management identified that they have designated individuals who are on call 24 hours/day for Ebola related calls.	
Team members will be proficient, given their respective roles and responsibilities during the transport	Y	I/P		Participants envisioned many potential events during transport, such as patient vomiting or becoming unstable. They expressed the need to plan for these events and clearly identify the most appropriate response. It was further expressed that HTMs would require practice and in-situ simulation in order to become proficient and assess the process.	Solution – The roles and responsibilities are being defined (i.e., through the walk-throughs). However, a plan is not yet in place for a practice using in situ simulation. Person Responsible – Timeline -

## G. Inter-hospital Patient Movement

			Documen	t Analysis	Qualitative Data	Proposed solutions
Result	Gap identified	Solution Implement	International Documents - WHO / CDC / Emory	National, Regional and Local - MOHLTC and TOH - CCCS - Public Health Agencies	Factors to be considered in the development and implementation of solutions	Description of solution, person responsible, timeline to implementation
The critical care team will be informed of any patient(s) with suspected or proven Ebola who might require ICU admission	N	Ν			On occasion, critically ill patients are admitted by other services without notifying the ICU. Participants emphasized the need to ensure that the CF and staff ICU physician be contacted prior to transport of any patient with suspected Ebola who may require ICU admission.	
There will be a clear process in place to ensure that the community hospitals receive all necessary information to initiate safe transport	N	Ν	EMORY <sup>4</sup> p.19-24 – Detailed Protocol for Biosafety Transport. Lists the level of precaution/PPE needed according to different infectious agents (including EVD). There is also a section on patient care during transport: • If the patient was exposed to an infectious agent, the transport		Participants stated that multiple services (ID, infection control, occupational health and safety, critical care, etc.) would likely need to be involved in the communication with the community hospital. They suggested that the roles and responsibilities of each service be clearly defined to optimize	

crow will onsure that the nationt	communication	
ciew will elisate that the patient	communication.	
was decontaininated at the site,	LITMA wave wet closes on the	
and may request that the patient		
wear a bionazard coverall as	appropriate response for patients	
noted in the specific levels of	directly referred to the ICU but who	
care above. If the patient cannot	do not require ICU admission. What	
tolerate the biohazard coverall,	should be the process to ensure that	
or the coverall is likely to	the patient be transferred to the	
interfere with patient care	most appropriate location. At	
activities, or the patient cannot	present, ICU physicians simply know	
assist in putting it on, the patient	to call ID.	
will be wrapped in an		
impervious sheet or similar		
barrier to prevent environmental		
contamination.		
<ul> <li>A temperature is to be recorded</li> </ul>		
on all patients.		
<ul> <li>A detailed History of Present</li> </ul>		
Illness (HPI) to include history of		
fever, cough, vomiting, diarrhea,		
hemorrhage, rash, malaise and		
duration of symptoms is to be		
obtained.		
<ul> <li>No IV is to be started on</li> </ul>		
patients unless the patient is in		
emergent need of volume		
replacement or reasonably		
expected to require IV		
medication.		
<ul> <li>No sharps are to be utilized in a</li> </ul>		
moving vehicle.		
<ul> <li>Large volumes of bodily effluent</li> </ul>		
are to be collected in leak proof		
containers that are either color		
coded as a biohazard or labeled		
with a biohazard sticker.		
<ul> <li>Any breach of infection control</li> </ul>		
measures is to be reported		
immediately to the special		
operations supervisor and		
program medical director.		
All transport personnel will		
comply with the surveillance		
policy as prescribed by EMS		
and the hospital infection control		
officer.		
All medical control questions will		
be directly communicated with		
the program medical director.		
NOT the usual decentralized		

			medical control system. Also a section on waste management and decontamination after transport of patient (see p.23- 24)		
There will be a plan of transport from entry point at our hospital to the ICU, which will minimize the risk of contamination	Y	N		<ul> <li>Numerous questions were raised by participants including:</li> <li>How to accept the patient from the transport team?</li> <li>Where the transport team will doff safely</li> <li>If the transport team enters the hospital do they need to decontaminate their feet or add a layer to their boots before walking in?</li> <li>If the patient is unstable or there is evidence of fluid contamination, does the transport team need to stop and decontaminate in ER before transporting the patient to the ICU?</li> </ul>	
There will be a clear process in place to ensure that the transfer of care in the ICU occurs safely for both the patient and staff	Y	N		Participants questioned whether the transport team would continue to manage the patient in the ICU while the ICU team donned their PPE. They expressed that this would need to be clearly defined, as this is not usual practice.	

## H. Critical Care management

			Document	Analysis	Qualitative Data	Proposed solutions
Result	Gap identified	Solution Implement	International Documents - WHO / CDC / Emory	National, Regional and Local - MOHLTC and TOH - CCCS - Public Health Agencies	Factors to be considered in the development and implementation of solutions	Description of solution, person responsible, timeline to implementation
HTMs will be supported in their decisions to withhold interventions in order to minimize the risk of spreading infection	N	Ν			Participants expressed concerns that withholding potentially life- saving procedures could increase morbidity and mortality. While this is troublesome under most circumstances, participants expressed that it would be even more troubling in patients who are subsequently found not to have Ebola.	

	HTMo will modify their		Ν	WHO <sup>5</sup> Quiding principal	CCCC <sup>8</sup> a 21 amount of time that	Given that there have been limited cases in the developed world, participants suggested that each case be reviewed and decisions made on an individual basis. The importance of collaborative decision making with colleagues was emphasized. Furthermore, the clinical ethicist has been identified and is available as a resource in difficult decision-making.	
I	clinical assessment to provide the best possible patient care while minimizing the risk of contamination.	Y	Ν	<ul> <li>WHO – Gulding principal – provide best medical care to improve survival while minimizing the risk of onward transmission to others.</li> <li>WHO<sup>5</sup> p. 23 - 25 – The initial clinical symptoms are non-specific and mimic many common infections. The HCW will expand their differential diagnosis to include other causes of fever and non-specific symptoms (e.g., malaria, typhoid, upper respiratory infections, urinary tract infections)</li> <li>WHO<sup>5</sup> – Have dedicated equipment for each patient (ex. Stethoscope)</li> </ul>	<ul> <li>HCP are exposed to the patient should be limited. Change in history taking and routine communication is needed (e.g., intercom, telephone, white board)</li> <li>CCCS<sup>8</sup> p.26 – Minimize patient transport. Consider portable investigation (Chest x-ray, ultrasound)</li> <li>CCCS<sup>8</sup> p.26 – "Given the limited diagnostic capabilities, it may be necessary to consider more liberal use of empiric therapies than is typical . In particular the two conditions in this group that must be considered and may warrant early empiric therapy if clinical risk factors exists and diagnostic investigations are delayed are: 1) Malaria, and 2) systemic bacterial infections."</li> <li>CCCS<sup>8</sup> p.28 – "Clinical examination of the patient should occur at least twice daily()"</li> </ul>	<ul> <li>Participants acknowledged the need to provide the best possible care while minimizing any nonessential contact. Activities should be planned to minimize the frequency of donning and doffing. Some activities will require coordination with other services (e.g. with housekeeping for removal of waste buckets from the room).</li> <li>Many participants expressed concerns about using a dedicated stethoscope, and felt the risk far outweighed the benefit. Suggestion was made to consider a dedicated electronic stethoscope with speaker.</li> </ul>	
	HTMs will modify non- invasive and invasive monitoring to provide the best possible patient care while minimizing the risk of contamination	Y	Y	<ul> <li>EMORY<sup>4</sup> p.15 –</li> <li>"All patients will have the following minimum orders as part of the admission protocol:</li> <li>Vital signs every 4 hours</li> <li>Daily weight</li> <li>Strict intake and output</li> <li>Nursing assessment each shift with particular attention to</li> </ul>	CCCS <sup>8</sup> p.30 – Minimal cardio- respiratory monitoring = EKG, O2 sat and NIBP. ETCO2 (p.32): should be considered in patients receiving mechanical ventilation ("the combination of ETCO2 monitoring and pulse oximetry may decrease the need for arterial blood gas	Participants reviewed the practices of HR, RR, O2 sat, NIBP, urine output, invasive arterial blood pressure monitoring, CVP, central venous O2 sat and ETCO2 monitoring. Participants emphasized the need to have dedicated and where possible disposable equipment.	Solution / Gap – could have used the wrong ETCO2 monitored. Added to ICU management plan to ensure newer one is used

		1				
			<ul> <li>presence of rash; mental status; lung and heart assessment; and presence of nausea, vomiting or diarrhea</li> <li>Complete Blood Count (CBC), Comprehensive Metabolic Panel (CMP), and urinalysis, on the day of admission and every three days thereafter "</li> </ul>	analysis")	The RTs expressed concerns with ETCO2 monitoring because installing the monitor requires a break in the ventilator circuit. They suggested using a transcutaneous CO2 monitor. Some RTs were not comfortable inserting arterial lines while others were comfortable with the procedure. Using a sutureless system was suggested as a measure to minimize risk of needle stick injury. The routine practice at this site is to suture arterial lines, hence it was suggested that in non- suspect Ebola cases the team could more frequently use sutureless systems to become more familiar with the process ensuring that they remain in place. In contrast, some HTMs had concerns that use of a sutureless would be outweighed by lines being accidentally pulled out thus increasing the risk of blood expression.	
There will be a clear process in place to perform CXRs and EKGs	Y	N	EMORY <sup>4</sup> p.35 – See Appendix 4 (Portable X-ray process for SCDU). They describe the steps for safe CXR in their unit (SCDU: "Serious Communicable Diseases Unit")		HTMs identified that there is currently no clear process in place and suggested to adapt the Emory protocol to our context. Participants noted that both the RN or RT can perform the EKG and hence an EKG technician will not be required.	
HTMs will take appropriate measures to decrease the risk of exposure to body fluids	N	N		<ul> <li>PHAC<sup>10</sup> – "Eating or drinking should not occur in areas where direct patient care is provided or in reprocessing or laboratory areas.</li> <li>HCWs with open skin areas/lesions on hands or forearms should not have contact with suspected or confirmed EVD cases or their environment.</li> <li>To prevent self-contamination, workers should avoid touching the mucous membranes of their eyes, nose and mouth with their hands."</li> <li>TOH – Use appropriate PPE. This included triple gloves when</li> </ul>	Participants indicated that NG, fecal collection system, Foley, etc. should be considered early in management. Participants also suggested obtaining disposable absorbable pads that turn liquid into gel to facilitate body fluid containment.	

				drawing blood. Once the specimen has been drawn, the outside of the specimen container must be wiped down with a hospital grade disinfectant prior to placing in biohazard bag. The HCW will then remove the outer layer pair of gloves and wipe down the outside of the bag with a Clorox wipe then place the biohazard bag in a second biohazard bag and seal. The HCW will then pass the bags out the door to a receiving person in the anteroom.		
HTMs will avoid using aerosol generating procedures (AGP) whenever possible	Y	Y	<ul> <li>Minimizing aerosol generating procedure</li> <li>CDC <sup>12</sup> – Surface cleaning mandated after AGPs</li> <li>CDC <sup>12</sup> – Use disposable facial masks (N95) because of potential contamination risk associated with reusable units (PAPR)</li> <li>CDC <sup>12</sup> –</li> <li>Avoid AGPs for patients with EVD.</li> <li>If performing AGPs, use a combination of measures to reduce exposures from aerosol-generating procedures when performed on Ebola HF patients.</li> <li>Visitors should not be present during aerosol-generating procedures.</li> <li>Limiting the number of HCP present during the procedure in a private room and ideally in an Airborne Infection Isolation Room (AIIR) when feasible. Room doors should be kept closed during the room, and entry and exit should be minimized</li> </ul>	<ul> <li>CCCS<sup>8</sup> – Airway/Breathing considerations</li> <li>NIV (p.33): Can be attempted but several limitations: <ol> <li>Frequent vomiting</li> <li>Prolongation of aerosolization risk</li> <li>If NIV failure, quick intubation might be difficult due to PPE donning (NIV trial requires close attention)</li> <li>Risk of oropharyngeal bleeding</li> </ol> </li> <li>Intubation (pp. 33-34): Important considerations: <ol> <li>Exhalation filter attached when bag ventilation provided</li> <li>Appropriate PPE must be worn (see PPE section or CSSS guidelines)</li> <li>Intubation by most experienced professional to limit manipulations</li> <li>Adjuncts to direct laryngoscopy should be considered to distance the clinician from the patient (i.e., video/optical laryngoscopy, etc.)</li> <li>Rapid sequence intubation protection preferred. Consider Ketamine or other agents that mitigate the post intubation hypotension</li> </ol></li></ul>	<ul> <li>Participants stated that it is preferable not to do any aerosol generating procedures.</li> <li>Participants suggested that the following procedures should never be performed: <ul> <li>BiPAP</li> <li>Nebulized meds</li> <li>Induced sputum</li> <li>In-Exsuffation</li> <li>Manual Lung volume recruitment</li> <li>Tracheostomy</li> <li>Nebulized Flolan</li> <li>High frequency oscillation</li> <li>Chest physiotherapy in spontaneously breathing patients.</li> </ul> </li> <li>Procedures that could generate aerosols if performed inappropriately require special attention including: <ul> <li>Closed in-line airway suctioning (only perform closed suctioning)</li> <li>Circuit manipulation</li> </ul> </li> <li>Participants suggested that the following procedures could be performed but only if absolutely necessary: <ul> <li>Bag-valve mask ventilation</li> <li>Intubation/extubation</li> </ul> </li> </ul>	Solution – Review of TOH list of AGP and interviews with key stakeholders to clarify and the list of aerosol generating procedures was broadened and each one explored to categorize into procedures which should never be done and those that could be considered if absolutely necessary.

	1	ale color as a se	al a la a stilla a fit a se tila a	0) Ob suid basis of surveys of the		
		during an	id shortly after the	6) Should be performed in	Nitric oxide	
		procedure	e.	negative pressure ventilation room	Proning	
		<ul> <li>HCP sho</li> </ul>	uld wear appropriate			
		PPE duri	ng aerosol	Mechanical Ventilation (p.35):	Participants felt that it would be	
		generatin	ig procedures.	ventilators must have capability for	important to develop procedures to	
				HEPA filtration of exhaled gases.	minimize aerosol generation.	
				In negative pressure ventilation	3	
				room. No recommendations on	With mechanical ventilation the	
				how to disinfect equipment. Make	AVEA ventilator is preferred with	
				reference to Emory's protocol	heated humidity and a HEPA	
				(equipment kept in room until	Omnifilter as it is easier to clean A	
				natient's discharge then	ventilator was identified that allows	
				disinfected by a company with	bronchoscopy with closed access	
				hydrogen perovide prior to its	(Kim Vent), however, we do not	
				return in circulation)	have this equipment. Derticipente	
					identified that the size of the sold part	
				MOULTC (Oct 20 <sup>th</sup> ) <sup>9</sup> p.9 limit	Identified that the circuit should not	
				number of propodures, $\lim_{n \to \infty} \frac{1}{n}$	be changed unless solled. Circuit	
				number of procedures. Limit	disconnection and openings should	
				number of staff present if AGP	be avoided.	
				requirea.		
				Recommended PPE = same +/-		
				PAPR		
				PHAC <sup>10</sup> – "Strategies to prevent		
				aerosol generation if AGPs are		
				absolutely necessary (e.g.		
				Intubation)		
				AGPs should not be performed on		
				patients suspected or confirmed to		
				have EVD.		
				If AGPs are absolutely necessary		
				(e.g. intubation), implement		
				strategies to reduce aerosol		
				generation:		
				AGPs should be anticipated and		
				planned for.		
				Appropriate patient sedation		
				should be used		
				The number of personnel in the		
				room should be limited to those		
				required to perform the AGP		
				AGPs should be performed in		
				airborne infection isolation rooms		
				(also referred to as negative		
				pressure rooms)		
				Appropriate ventilation (e.g. level		
				of air filtration and direction of air		
				flow) should be maintained		
				Single rooms (with the door closed		
				and away from other nationta)		
				and away norm other patients),		

			should be used in settings where airborne infection isolation rooms are unavailable. Fit tested respirators (seal- checked NIOSH approved N95 at minimum) should be worn by all personnel in the room during the procedure. Closed endotracheal suction systems should be used wherever possible."		
			<b>TOH</b> – IPC policy and procedure manual on aerosol generating respiratory procedures - Aerosol-generating respiratory procedures (see list of procedures in document) prevention measures can be instituted by any regulated HCP. The procedure must be performed by an experienced HCP. When possible, avoid initiation of aerosol generating respiratory procedures. Carefully assess the benefit of the procedure versus the potential occupational risk		
HTMs will take measures to safely obtain central access when required	Y	Y	CCCS <sup>®</sup> p.31 – Central line not indicated for CVP monitoring If central line established for alternative reasons (difficult peripheral access, requirement of vasopressors, electrolytes replacement), CVP monitoring can be considered. "Central venous access has been required in the management of the majority of EVD patients treated in 'Western' health care systems due to a) the requirement for aggressive potassium replacement and b) difficulty in obtaining peripheral venous access due to edema." CCCS <sup>®</sup> p.35-36 – "In the early states of EVD and for those with milder manifestations of the illness peripheral IV access is suitable for	Participants agreed that only experienced staff should perform the procedure. Some physicians were very comfortable inserting central lines blindly while others were more comfortable with ultrasound guided line insertion. It was highlighted that some guidelines recommended ultrasound guided line insertion and that use of ultrasound could decrease the risk of complications and body fluid exposure (e.g. arterial puncture or pneumothorax requiring chest tube insertion). Concerns were expressed regarding the use of the newest M-turbo ultrasound machine, because it was felt that it would be difficult to decontaminate and was in frequent use for other ICU patients.	Solution - Physicians suggested that an older, yet suitable, ultrasound model for line insertion, could be dedicated to the room.

		1		<b>G</b> : 1 ( )		
				fluid management." CCCS <sup>8</sup> p.36 – " Central or peripheral inserted central venous access should be considered for patients who require electrolyte replacement, vasopressors, or where vascular collapse limits peripheral IV access ()" CCCS <sup>8</sup> p.36 – Minimize risks with ultrasound guidance. Consider non-suture securing devices to minimize skin punctures		
HTMs will safely draw blood	Y	I/P	<ul> <li>CDC <sup>12</sup> – "Limit the use of needles and other sharps as much as possible"</li> <li>WHO<sup>5</sup> p. 50 – Limit the use of needles and other sharp objects as much as possible. Limit the use of phlebotomy and laboratory testing to the minimum necessary for essential diagnostic evaluation and patient care.</li> <li>CDC<sup>15</sup> – "Any person collecting specimens from a patient with a case of suspected Ebola virus disease should wear gloves, waterresistant gowns, full face shield or goggles, and masks to cover all of nose and mouth"</li> <li>CDC<sup>15</sup> – Transportation of specimens: "()specimens should be placed in a durable, leak-proof secondary container for transport within a facility. To reduce the risk of breakage or leaks, do not use any pneumatic tube system for transporting suspected EVD specimens." (Schema example in the CDC guideline)</li> <li>Prefered specimen: "A minimum volume of 4mL whole blood in <i>plastic</i> collection tubes can be used to submit specimens</li> </ul>	TOH – Blood draw guidelines for patient with suspected or confirmed Ebola MOHLTC (Oct 30 <sup>th</sup> ) <sup>9</sup> p.7 - "Use of needles and sharps should be kept to a minimum and for medically essential procedures only. The requirements of the Needle Safety Regulation (O. Reg. 474/07) under the Occupational Health and Safety Act must be met. Extreme care should be used when handling sharps. A puncture- resistant sharps container must be available at point of use. The risk of transmission of EVD through percutaneous injury is high; therefore, the most experienced HCWs in drawing bloods or starting lines (e.g. IV, arterial) should perform these tasks."	HTMs expressed concerns about drawing blood according to the current Ebola protocol, as they had not received training on how to perform the procedure. In our ICU we have a satellite blood gas machine, It was identified by participants that any blood gas drawn should go to the main lab and that HTMs need to be aware of this. It was further suggested that the timing of the ABGs should be timed with other blood work to minimize transport.	Education and practice is being organized as part of the simulation lab training.

for testing for Ebola vitus. Do not submit specimens to CDC in glass containers or in heparinized tubes. Whole blood preserved with EboTA in reserved with sodium polyanethol submit (SPS), citrate, or with dot activator is acceptable. It is not necessary to separate and remove serum or plasma from the primary collection container. Specimens should be immediately subce of transported at the CDC <sup>*</sup> Also – Limit the use of needles and other entry for the collection to the reserved with sodium polyanethol subtract of transported at the CDC <sup>*</sup> Also – Limit the use of needles and other entry for the collection and medical care All needles and sharps should be handled with extreme care and disposed in purcular-prof, sealed containers ELINON <sup>+</sup> (p.45) – A vary detailed profilection in the dot of the row collection and medical care ELINON <sup>+</sup> (p.45) – A vary detailed profilection in the objection and medical and the speciment tubes EMON <sup>+</sup> (p.45) – A papendix 6 Protocol for transport of specimen tubes WHol <sup>+</sup> 0, 8 - INLECTION SAFETY AND MANACENENTO F SHARPS • Each patient should have exclusively dedicated injection and aprenterial medication equipment.				
submit specimens to CDC in glass containers or the heparitized tubes. Whole blood preserved with EDTA is preferred but whole blood preserved with a dotter preserved with a dotter preserved with a contempositive acceptable. It is not necessary to separate and remove serum or plasma from the primary collection container. Specimens should be immediately stored or transported at 2-8°C or fraze on cold-packs to the CDC <sup>C</sup> Also – Limit the use of needles and other sharps as much as possible Phebotomy, procedures, and laboratory testing should be limited to the minimum necessary for essential disposite evaluation and medical care All needles and sharps should be handled with extreme care and disposed in puncture proof, eselled containers EMORY <sup>4</sup> p.45 – A very detailed protocol on how to perform phebotomy. Usion dispection to document. EMORY <sup>4</sup> p.45 – A very detailed protocol for transported to document. EMORY <sup>4</sup> p.45 – A very detailed protocol for transport of specimen tubes WHO <sup>5</sup> p. 8 - NUECTION SAFETY AND MANAGEMENT OF SHARPS • Each patient should have exclusively dedicated injection and parenterrail medication equipment, which should be disposed of at the point of care. Syringes, medicate or smaller equipment		for testing for Ebola virus. Do not		
containers or in heparinized tubes.         Whole blood preserved with EDTA is preferred but whole blood preserved with is addum poyanethol subtonate (SPS), chirate.or with loot activator is acceptable. It is not necessary to separate and reinove serum of potential control and potential container: Specimens should be immediately solved or transported at 2.8°C or forzen on cold-packs to the CDC*         Also -       Limit the use of needles and other sharps as much as possible Philebolomy, procedures, and laboratory testing should be limited to the minimum necessary for essential diapositic evaluation and alsocated in theorem care and disposed in puncture-proof, sealed containers         EMORY* p.6-9 - A very detailed protocol on how to perform philebolomy, flood test is available in their document (refer to document)         EMORY* p.6-9 - A very detailed protocol for transport of specimen tubes         WHO* p.8 - NUECTION SAFETY AND MANAGEMENT OF SHARPS         • EMORY* p.6-1 patient should have exclusively dedicated injection and parenteral medication equipment, which should be disposed of at the priot of care. Syringes, medicate or should requipment.		submit specimens to CDC in glass		
Whole blood preserved with EDTA is preferred but whole blood preserved with; sodium polyamethol subtrate (1950), citrate, or with clot activator is acceptable. It is not necessary to separate and remove serum or container. Specimens should be immediately stored or transported at 2.8°C or frace on cold-packs to the CDC <sup>-</sup> Also - Eurint the use of needles and other sharps as much as possible that any container. Specimens should be immediately stored or transported to the minimum necessary for essential diagnostic evaluation and medical care All needles and sharps should be handled with extreme care and disposed in puncture-proof, seelied containers         EMORY <sup>4</sup> p.45 - A very detailed protocol on how to perform their document (refer to document)         EMORY <sup>4</sup> p.45 - Appendix 6 Protocol for transport of specimen tubes         WHO <sup>6</sup> 7, 8 - INLECTION SAFETY AND SHARPS         • Each patient should have exclusively deficated injection and parenterail medicator equipment, which should be disposed of at the point of care. Springes, medicase or small equipment.		containers or in heparinized tubes.		
is preferred but whole blood preserved with, sodium polyanethol sulfonate (SPS), oftrate, or with cold activator is acceptable. It is not necessary to separate and remove serum or plasma from the primary collection container. Specimers should be immediately stored or transported at eCOC frozon on cold-packs to the COC. Also – Limit the use of needles and other sharps as much as possible Philebotomy, procedures, and laboratory testing should be limited to the minimum necessary for essential diagnostic evaluation and medical care Andred with extreme carts and diagnostic evaluation and medical care Andred with extreme carts and diagnostic evaluation and medical care Andred with extreme carts and hardled with blood test is available in their document (refer to document) EMORY <sup>4</sup> p. 45 – Appendix 6 Priotocol to how to perform philebotomy blood test is available in their document (refer to document) EMORY <sup>4</sup> p. 45 – Appendix 6 Priotocol to transport of specimen tubes WHO <sup>5</sup> p. 8 - INJECTION SAFETY AND MANAGEMENT OF SHARPS • Each patient should have exclusively dedicated nigedical on diagnement, which should be disposed of at the point of care. Syringes, necesses or smalar equipment		Whole blood preserved with EDTA		
preserved with sodium polyamethol sufmate (SPS), citrite, or with cit advator is acceptable. It is not necessary to separate and remove serum or plasma form the primary collection container. Specimens should be immediately stored or transported at 2.8°C or frozen on cold-packs to the CDC <sup>2</sup> Also - Limit the use of needles and other that built built built built built built to CDC <sup>3</sup> Philobotomy procedures, and laboratory testing should be limited to the minimum necessary for essential diagnostic evaluation and medical care All needles and sharps should be handled with waterne care and disposed in puncture-proof, sealed containers available in their document (refer to document) EMORY <sup>4</sup> p.45 – Apendix 6 Protocol for transport of specimen tubes WH0 <sup>5</sup> p. 8 - INJECTION SAFETY AND MANAGEMENT OF SHARPS • Each patient should have exclusively dedicated injection edgament, which should be disposed of at the point of care. Syringes, needles or smutar equipment		is preferred but whole blood		
acceptable. It is not necessary to separate and remove serum or plasma from the primary collection container. Specimens should be immediately stored or transported at 12-8°C of trozen on cold-packs to the CDC*         Also -         Limit the use of needles and other sharps as much as possible Philobotimy, procedures, and laboratory testing should be immediately stored or transported at a diagnostic evaluation and medical care         Also -         Limit the use of needles and other sharps as much as possible Philobotimy, procedures, and laboratory testing should be limited to the minimum necessary for essential diagnostic evaluation and medical care         All meedles and sharps should be limited to the minimum necessary for essential diagnostic evaluation and medical care         All meedles and sharps should be limited to the minimum necessary for essential diagnostic evaluation and medical care         All meedles and sharps should be limited to the minimum necessary for essential diagnostic evaluation and medical care         All meedles and sharps should be limited to the minimum necessary for essential diagnostic evaluation and medical care         All meedles and sharps should be limited to the minimum necessary for essential diagnostic evaluation and medical care         All meedles and sharps charped to the discussed of the protocol on how to perform philebotomy. J blocd test is available in their document (refer to document)         EMORY* p.45 - Appendix 6         Protocol for transport of specimen tubes         WHO <sup>2</sup> p. 6 INJECTION SAFETY         All medication equipment, which should have exclusively ded		preserved with: sodium		
b) drate, or with cital activative capacity is it remove secure or plasma from the primary collection container. Specimens should be immediately stored or transported at 2-8°C or frazen on cold-packs to the COC* Also – Limit the use of needies and other sharps as much as possible Phebotomy, procedures, and laboratory testing should be limited to the minimum necessary for essential diagnostic evaluation and medical care All needles and sharps should be handled with extreme care and disposed in puncture-proof, sealed containers EMORY <sup>4</sup> p.6-9 – A very detailed protocol no how to perform phiebotomy, biodot test is available in their document (refer to document) EMORY <sup>4</sup> p.6-9 – A very detailed Protocol for transport of specimen tubes WHO <sup>5</sup> p. 8 - INUECTION SAFETY AND MANAGEMENT OF SHARPS • Each patient should have exclusively dedicated injection and parenteral medication equipment, which should be disposed of at the point of care. Syringes.		preserved with, solidin		
Cliniter, of Wint 15 in oth necessary to patients from the primary collection container. Specimens should be immediately stored or transported at 2-8°C or forcen on cold-packs to the CDC*         Also -         Limit the use of needles and other sharps as much as possible Philebotomy, procedures, and laboratory testing should be limited to the minimum necessary for essential diagnostic evaluation and medical care         All needles and sharps should be handled with extrem care and disposed in puncture-proof, sealed containers         EMORY <sup>4</sup> p. 6-9 - A vary detailed protocol no how to perform philebotomy / blood test is available in their document (refer to document)         EMORY <sup>4</sup> p. 6 - Appendix 6 Protocol for transport of specimen tubes         WHO <sup>7</sup> p. 8 - INJECTION SAFETY AND MANAGEMENT OF SHARPS         • Each patient should have exclusively dedicated injection and parenteral medication equipment, which should be disposed of at the point of care. Syringes, needles or smint equipment		polyanethol sunonate (SFS),		
abceptable. It is not necessary to         separate and remove serving or plasma from the primary collection         container. Specimens should be         immediately stored or transported         at 2+5° to frozen on cold-packs to         the COC*         Also –         Limit the use of needles and other         sharps at much as possible         Philebolomy, procedures, and         laboratory testing should be limited         to the minimum necessary for         essential diagnostic evaluation         and medical care         All needles and sharps should be         handled with extreme care and         disposed in puncture-proof, sealed         containers         EMORY <sup>4</sup> p.6-9 – A very detailed         protocol on how to perform         phetotomy / blood test is         available in their document (refer         to document)         EMORY <sup>4</sup> p.45 – Appendix 6         Protocol for transport of specimen         tubes         WHO <sup>7</sup> p. 8 - INJECTION SAFETY         AND MANAGEMENT OF         SHARPS         • Each patient should have         exclusively dedicated         injectical on a quipment, which         should be disposed of at the		citrate, or with clot activator is		
separate and remove serum or plasma from the primary collection container. Specimens should be immediately stored or transported at 2.8°C or frozen on cold-packs to the CDC'         Also –       Limit the use of needles and other sharps as much as possible Philebotomy, procedures, and laboratory testing should be limited to the minimum necessary for essential diagnosite evaluation and medical care         All needles and sharps should be handled with extreme care and disposed in puncture-proof, sealed containers         EMORY <sup>4</sup> p.6.9 – A very detailed protocol on how to perform philebotomy / blood test is available in their document (refer to document)         EMORY <sup>4</sup> p.6.9 – A very detailed protocol for transport of specimen tubes         WH0 <sup>7</sup> p. 8.1 - INJECTION SAFETY AND MANAGEMENT OF SHARPS         •       Each patient should have exclusively deticated an equipment, which should be disposed of at the point of care. Syringes.		acceptable. It is not necessary to		
plasma from the primary collection         container, Specimens should be         immediately stored or transported         at 2.8°C of forzen on cold-packs to         the CDC'         Also –         Limit the use of needles and other         sharps as much as possible         Phiebotomy, procedures, and         laboratory testing should be limited         to the minimum necessary for         essential diagnostic evaluation         and medical care         All needles and sharps should be         handled with extrem care and         disposed in puncture-proof, sealed         containers         EMORY <sup>4</sup> p.6-9 – A very detailed         protocol on how to perform         phebotomy / blood test is         available in their document (refer         to document)         EMORY <sup>4</sup> p.5 – A papendix 6         Protocol for transport of specimen         tubes         WHO <sup>7</sup> p. 8 - INJECTION SAFETY         AND MANAGEMENT OF         SHARPS         Each patient should have         exclusively dedicated         injection and parenteral         medication equipment, which         should be disposed of at the         point of care. Syringes,		separate and remove serum or		
container. Specimens should be immediately stored or transported at 2-8°C or frozen on cold-packs to the CDC"         Also –         Limit the use of needles and other sharps as much as possible Philebotomy, procedures, and laboratory testing should be limited to the minimum necessary for essentia diagnostic evaluation and medical care         All needles and sharps should be handled with extreme care and disposed in puncture-proof, sealed containers         EMORY <sup>4</sup> p.6-9 – A very detailed protocol on how to perform philebotomy / biood lest is available in their document (refer to document)         EMORY <sup>4</sup> p.45 – Appendix 6 Protocol for transport of specimen tubes         WHO <sup>7</sup> p. 8 - INJECTION SAFETY AND MANAGEMENT OF SHARPS         • Each patient should have exclusively dedicated injection and partneriterial medication equipment, which should be disposed of at the point of care. Syringes, needles or similar equipment		plasma from the primary collection		
immediately stored or transported         at 2-8° Cor frazen on cold-packs to         Also -         Limit the use of needles and other         sharps as much as possible         Phiebotomy, procedures, and         laboratory testing should be limited         to the minimum necessary for         essential diagnostic evaluation         and medical care         All needles and sharps should be handled with extreme care and         disposed in puncture-proof, sealed         containers         EMORY <sup>4</sup> p.6-9 - A very detailed         protocol on how to perform         phiebotomy / blood test is         available in their document (refer         to document)         EMORY <sup>4</sup> p.45 - Appendix 6         Protocol for transport of specimen         tubes         VHO <sup>5</sup> p. 8 - INJECTION SAFETY         AND MANAGEMENT OF         SHARPS         • Each patient should have         exclusively dedicated         injection and patienterial         medication equipment, which         should be disposed of at the         point of care. Syringes,         • Each patient should have         exclusively dedicated         injection and patenteris/         medication		container. Specimens should be		
at 2-8°C or frozen on cold-packs to         the CDC°         Also -         Limit the use of needles and other         Philebotomy, procedures, and         laboratory testing should be limited         to the minimum necessary for         essential diagnostic evaluation         and medical care         All needles and sharps should be         handled with extreme care and         disposed in protucture-proof, sealed         containers         EMORY <sup>4</sup> p.6-9 – A very detailed         protocol on how to perform         philebotiny / blood test is         available in their document (refer         to document)         EMORY <sup>4</sup> p.45 – Appendix 6         Protocol for transport of specimen         tubes         WHO <sup>7</sup> p. 8 - INJECTION SAFETY         AND MANAGEMENT OF         SHARPS         •       Each patient should have         exolusively deficiteded         injection and parenteral         medication equipment, which         should be disposed of at the         point of care. Syringes,         neceles or smillant equipment		immediately stored or transported		
the CDC"         Also –         Limit the use of needles and other         sharps as much as possible         Philebotomy, procedures, and         laboratory testing should be limited         to the minimum necessary for         essential diagnostic evaluation         and medical care         All needles and sharps should be         handled with extreme care and         disposed in puncture-prof, sealed         containers         EMORY* p.6-9 – A very detailed         protocol on how to perform         philebotomy / blood test is         available in their document (refer         to document)         EMORY* p.6-3 – Appendix 6         Pholocol for transport of specimen         tubes         WHO <sup>7</sup> p. 8 - INJECTION SAFETY         AND MANAGEMENT OF         SHARPS         •       Each patient should have         exclusively deficitated         injection and parenteral         medication equipment, which         should be disposed of at the         point of care. Syringes,         needles or similar equipment		at 2-8°C or frozen on cold-packs to		
Also –         Limit the use of needless and other         sharps as much as possible         Phiebotomy, procedures, and         laboratory testing should be limited         to the minimum necessary for         essential diagnostic evaluation         and medical care         All needles and sharps should be         handled with extreme care and         disposed in puncture-proof, sealed         containers         EMORY <sup>4</sup> p.5-9 – A very detailed         protocol on how to perform         philebotomy / blood test is         available in their document (refer         to document)         EMORY <sup>4</sup> p.45 – Appendix 6         Protocol for transport of specimen         tubes         WHO <sup>7</sup> p. 8 - INJECTION SAFETY         AND MANAGEMENT OF         SHARPS         •       Each patient should have         exclusively deficiated         injection and parenteral         medication equipment, which         should be disposed of at the         point of care. Syringes,         needles or situate equipment		the CDC"		
Also -         Limit the use of needles and other         sharps as much as possible         Phiebodomy, procedures, and         laboratory testing should be limited         to the minimum necessary for         essential diagnostic evaluation         and medical care         All needles and sharps should be         handled with extreme care and         disposed in puncture-proof, sealed         containers         EMORY <sup>4</sup> p.6-9 – A very detailed         protocol on how to perform         philebotomy,/ blood test is         available in their document (refer         to document)         EMORY <sup>4</sup> p.45 – Appendix 6         Protocol for transport of specimen         tubes         wHO <sup>7</sup> p. 8 - INJECTION SAFETY         AND MANAGEMENT OF         SHARPS         •       Each patient should have         exclusively dedicated         injection and parenteral         medication equipment, which         should be disposed of at the         point of care. Syringes,         needles or shinar equipment				
Limit the use of needles and other sharps as much as possible Philebotomy, procedures, and laboratory testing should be limited to the minimum necessary for essential diagnostic evaluation and medical care All needles and sharps should be handled with extreme care and disposed in puncture-proof, sealed containers EMORY <sup>4</sup> p.6-9 – A very detailed protocol on how to perform philebotomy/ blood test is available in their document (refer to document) EMORY <sup>4</sup> p.45 – Appendix 6 Protocol for transport of specimen tubes WHO <sup>7</sup> p. 8 - INJECTION SAFETY AND MANAGEMENT OF SHARPS • Each patient should have exclusively dedicated injection and parenteral medication equipment, which should be disposed of at the point of care. Syringes, needles or similar equipment		Also –		
sharps as much as possible         Philebotomy, procedures, and         laboratory testing should be limited         to the minimum necessary for         essential diagnostic evaluation         and medical care         All needles and sharps should be         handled with extreme care and         disposed in puncture-proof, sealed         containers         EMORY <sup>4</sup> p.6-9 – A very detailed         protocol on how to perform         philebotomy / blood test is         available in their document (refer         to document)         EMORY <sup>4</sup> p.45 – Appendix 6         Protocol for transport of specimen         tubes         WHO <sup>7</sup> p. 8 - INJECTION SAFETY         AND MANAGEMENT OF         SHARPS         • Each patient should have         exclusively dedicated         injection and parenteral         medication equipment, which         should be disposed of at the         point of care. Syringes,         needles or similar equipment		Limit the use of needles and other		
Philebotomy, procedures, and laboratory testing should be limited to the minimum necessary for essential diagnostic evaluation and medical care All needles and sharps should be handled with extreme care and disposed in puncture-proof, sealed containers         EMORY <sup>4</sup> p.6-9 – A very detailed protocol on how to perform philebotomy / blood test is available in their document (refer to document)         EMORY <sup>4</sup> p.45 – Appendix 6 Protocol for transport of specimen tubes         WHO <sup>7</sup> p. 8 - INJECTION SAFETY AND MANAGEMENT OF SHARPS         • Each patient should have exclusively dedicated injection and parenteral medication equipment, which should be disposed of at the point of care. Syringes, needles or similiar equipment		sharps as much as possible		
Iaboratory lesting should be limited to the minimum necessary for essential diagnostic evaluation and medical care         All needles and sharps should be handled with extreme care and disposed in puncture-proof, sealed containers         EMORY <sup>4</sup> p.6-9 – A very detailed protocol on how to perform phlebotomy / blood test is available in their document (refer to document)         EMORY <sup>4</sup> p.6-1 – Appendix 6 Protocol for transport of specimen tubes         WHO <sup>7</sup> p. 8 - INJECTION SAFETY AND MANAGEMENT OF SHARPS         • Each patient should have exclusively dedicated injection and parenteral medication equipment, which should be disposed of at the point of care. Syringes, needles or similiar equipment		Phlebotomy procedures and		
In the minimum necessary for essential diagnostic evaluation and medical care All needles and sharps should be handled with extreme care and disposed in puncture-proof, sealed containers         EMORY <sup>4</sup> p.6-9 – A very detailed protocol on how to perform philebotomy / blood test is available in their document (refer to document)         EMORY <sup>4</sup> p.45 – Appendix 6 Protocol for transport of specimen tubes         WHO <sup>7</sup> p. 8 - INJECTION SAFETY AND MANAGEMENT OF SHARPS         • Each patient should have exclusively dedicated injection and parenteral medication equipment, which should be disposed of at the point of care. Syringes, needles or similar equipment		laboratory testing should be limited		
essential diagnostic evaluation and medical care All needles and sharps should be handled with extreme care and disposed in puncture-proof, sealed containers EMORY <sup>4</sup> p.6-9 – A very detailed protocol on how to perform phlebotomy / blood test is available in their document (refer to document) EMORY <sup>4</sup> p.45 – Appendix 6 Protocol for transport of specimen tubes WHO <sup>7</sup> p. 8 - INJECTION SAFETY AND MANAGEMENT OF SHARPS • Each patient should have exclusively dedicated injection and parenteral medication equipment, which should be disposed of at the point of care. Syringes, needles or similar equipment		to the minimum percessary for		
essential dagliostic evaluation         and medical care         All needles and sharps should be         handled with exteme care and         disposed in puncture-proof, sealed         containers         EMORY <sup>4</sup> p.6.9 – A very detailed         protocol on how to perform         philebotomy / blood test is         available in their document (refer         to document)         EMORY <sup>4</sup> p.45 – Appendix 6         Protocol for transport of specimen         tubes         WHO <sup>7</sup> p. 8 - INJECTION SAFETY         AND MANACEMENT OF         SHARPS         • Each patient should have         exclusively dedicated         injection and parenteral         medication equipment, which         should be disposed of at the         point of care. Syringes,         needles or similar equipment		concerning diagnostic evaluation		
All needles and sharps should be handled with extreme care and disposed in puncture-proof, sealed containers EMORY <sup>4</sup> p.6-9 – A very detailed protocol on how to perform philebotomy / blood test is available in their document (refer to document) EMORY <sup>4</sup> p.45 – Appendix 6 Protocol for transport of specimen tubes WHO <sup>7</sup> p. 8 - INJECTION SAFETY AND MANAGEMENT OF SHARPS • Each patient should have exclusively dedicated injection and parenteral medication equipment, which should be disposed of at the point of care. Syringes, needles or similar equipment		essential diagnostic evaluation		
All needles and sharps should be handled with extreme care and disposed in puncture-proof, sealed containers EMORY <sup>4</sup> p.6-9 – A very detailed protocol on how to perform phlebotomy / blood test is available in their document (refer to document) EMORY <sup>4</sup> p.45 – Appendix 6 Protocol for transport of specimen tubes WHO <sup>7</sup> p. 8 - INJECTION SAFETY AND MANAGEMENT OF SHARPS • Each patient should have exclusively dedicated injection and parenteral medication equipment, which should be disposed of at the point of care. Syringes, needles or similar equipment				
handled with extreme care and disposed in puncture-proof, sealed containers EMORY <sup>4</sup> p.6-9 – A very detailed protocol on how to perform phiebotomy / blood test is available in their document (refer to document) EMORY <sup>4</sup> p.45 – Appendix 6 Protocol for transport of specimen tubes WHO <sup>7</sup> p. 8 - INJECTION SAFETY AND MANAGEMENT OF SHARPS • Each patient should have exclusively dedicated injection and parenteral medication equipment, which should be disposed of at the point of care. Syringes, needles or similar equipment		All needles and snarps should be		
disposed in puncture-proof, sealed containers         EMORY <sup>4</sup> p.6-9 – A very detailed protocol on how to perform philebotomy / blood test is available in their document (refer to document)         EMORY <sup>4</sup> p.45 – Appendix 6 Protocol for transport of specimen tubes         WHO <sup>7</sup> p. 8 - INJECTION SAFETY AND MANAGEMENT OF SHARPS         • Each patient should have exclusively dedicated injection and parenteral medication equipment, which should be disposed of at the point of care. Syringes, needles or similar equipment		handled with extreme care and		
containers         EMORY <sup>4</sup> p.6-9 – A very detailed protocol on how to perform phebotomy / blood test is available in their document (refer to document)         EMORY <sup>4</sup> p.45 – Appendix 6 Protocol for transport of specimen tubes         WHO <sup>7</sup> p. 8 - INJECTION SAFETY AND MANAGEMENT OF SHARPS         • Each patient should have exclusively dedicated injection and parenteral medication equipment, which should be disposed of at the point of care. Syringes, needles or similar equipment		disposed in puncture-proof, sealed		
EMORY <sup>4</sup> p.6-9 – A very detailed protocol on how to perform phlebotomy / blood test is available in their document (refer to document)         EMORY <sup>4</sup> p.45 – Appendix 6 Protocol for transport of specimen tubes         WHO <sup>7</sup> p. 8 - INJECTION SAFETY AND MANAGEMENT OF SHARPS         • Each patient should have exclusively dedicated injection and parenteral medication equipment doing do the point of care. Syringes, needles or similar equipment		containers		
<ul> <li>EMORY* p.6-9 – A very detailed protocol on how to perform phelebotomy / blood test is available in their document (refer to document)</li> <li>EMORY* p.645 – Appendix 6 Protocol for transport of specimen tubes</li> <li>WHO<sup>7</sup> p. 8 - INJECTION SAFETY AND MANAGEMENT OF SHARPS</li> <li>Each patient should have exclusively dedicated injection and parenteral medication equipment, which should be disposed of at the point of care. Syringes, needles or similar equipment</li> </ul>				
protocol on how to perform         phlebotomy / blood test is         available in their document (refer         to document)         EMORY <sup>4</sup> p.45 – Appendix 6         Protocol for transport of specimen         tubes         WHO <sup>7</sup> p. 8 - INJECTION SAFETY         AND MANAGEMENT OF         SHARPS         • Each patient should have         exclusively dedicated         injection and parenteral         medication equipment, which         should be disposed of at the         point of care. Syringes,         needles or similar equipment		EMORY <sup>4</sup> p.6-9 – A very detailed		
phlebotomy / blood test is         available in their document (refer         to document)         EMORY <sup>4</sup> p.45 – Appendix 6         Protocol for transport of specimen         tubes         WHO <sup>7</sup> p. 8 - INJECTION SAFETY         AND MANAGEMENT OF         SHARPS         • Each patient should have         exclusively dedicated         injection and parenteral         medication equipment, which         should be disposed of at the         point of care. Syringes,         needles or similar equipment		protocol on how to perform		
available in their document (refer         to document)         EMORY <sup>4</sup> p.45 – Appendix 6         Protocol for transport of specimen         tubes         WHO <sup>7</sup> p. 8 - INJECTION SAFETY         AND MANAGEMENT OF         SHARPS         •       Each patient should have         exclusively dedicated         injection and parenteral         medication equipment, which         should be disposed of at the         point of care. Syringes,         needles or similar equipment		phlebotomy / blood test is		
to document) EMORY <sup>4</sup> p.45 – Appendix 6 Protocol for transport of specimen tubes WHO <sup>7</sup> p. 8 - INJECTION SAFETY AND MANAGEMENT OF SHARPS • Each patient should have exclusively dedicated injection and parenteral medication equipment, which should be disposed of at the point of care. Syringes, needles or similar equipment		available in their document (refer		
<ul> <li>EMORY<sup>4</sup> p.45 – Appendix 6 Protocol for transport of specimen tubes</li> <li>WHO<sup>7</sup> p. 8 - INJECTION SAFETY AND MANAGEMENT OF SHARPS</li> <li>Each patient should have exclusively dedicated injection and parenteral medication equipment, which should be disposed of at the point of care. Syringes, needles or similar equipment obside anote be support</li> </ul>		to document)		
<ul> <li>EMORY<sup>4</sup> p.45 – Appendix 6 Protocol for transport of specimen tubes</li> <li>WHO<sup>7</sup> p. 8 - INJECTION SAFETY AND MANAGEMENT OF SHARPS</li> <li>Each patient should have exclusively dedicated injection and parenteral medication equipment, which should be disposed of at the point of care. Syringes, needles or similar equipment</li> </ul>				
Protocol for transport of specimen tubes WHO <sup>7</sup> p. 8 - INJECTION SAFETY AND MANAGEMENT OF SHARPS • Each patient should have exclusively dedicated injection and parenteral medication equipment, which should be disposed of at the point of care. Syringes, needles or similar equipment elevel accurate to remove		EMORY <sup>4</sup> p.45 – Appendix 6		
tubes         WHO <sup>7</sup> p. 8 - INJECTION SAFETY AND MANAGEMENT OF SHARPS         • Each patient should have exclusively dedicated injection and parenteral medication equipment, which should be disposed of at the point of care. Syringes, needles or similar equipment exclusive be reward		Protocol for transport of specimen		
<ul> <li>WHO<sup>7</sup> p. 8 - INJECTION SAFETY AND MANAGEMENT OF SHARPS</li> <li>Each patient should have exclusively dedicated injection and parenteral medication equipment, which should be disposed of at the point of care. Syringes, needles or similar equipment</li> </ul>		tubes		
<ul> <li>WHO<sup>7</sup> p. 8 - INJECTION SAFETY AND MANAGEMENT OF SHARPS</li> <li>Each patient should have exclusively dedicated injection and parenteral medication equipment, which should be disposed of at the point of care. Syringes, needles or similar equipment</li> </ul>				
AND MANAGEMENT OF SHARPS • Each patient should have exclusively dedicated injection and parenteral medication equipment, which should be disposed of at the point of care. Syringes, needles or similar equipment		WHO <sup>7</sup> p. 8 - INJECTION SAFETY		
<ul> <li>SHARPS</li> <li>Each patient should have exclusively dedicated injection and parenteral medication equipment, which should be disposed of at the point of care. Syringes, needles or similar equipment eheud neurond</li> </ul>		AND MANAGEMENT OF		
<ul> <li>Each patient should have exclusively dedicated injection and parenteral medication equipment, which should be disposed of at the point of care. Syringes, needles or similar equipment</li> </ul>		SHARPS		
<ul> <li>Each patient should have exclusively dedicated injection and parenteral medication equipment, which should be disposed of at the point of care. Syringes, needles or similar equipment</li> </ul>		• Fach nations - hould have		
exclusively dedicated injection and parenteral medication equipment, which should be disposed of at the point of care. Syringes, needles or similar equipment		<ul> <li>Each patient should have</li> </ul>		
injection and parenteral medication equipment, which should be disposed of at the point of care. Syringes, needles or similar equipment ehould person be record		exclusively dedicated		
medication equipment, which should be disposed of at the point of care. Syringes, needles or similar equipment ehould prove he reveal		injection and parenteral		
should be disposed of at the point of care. Syringes, needles or similar equipment		medication equipment, which		
point of care. Syringes, needles or similar equipment		should be disposed of at the		
needles or similar equipment		point of care. Syringes,		
about a power be reused		needles or similar equipment		
snoula never de reusea.		should never be reused.		

	<ul> <li>Limit the use of needles and other sharp objects as much as possible.</li> </ul>
	<ul> <li>Limit the use of phlebotomy and laboratory testing to the minimum necessary for essential diagnostic evaluation and patient care.</li> </ul>
	<ul> <li>If the use of sharp objects cannot be avoided, ensure the following precautions are observed:</li> </ul>
	<ul> <li>Never replace the cap on a used needle.</li> <li>Never direct the point of a used needle towards any part of the body.</li> </ul>
	<ul> <li>Do not remove used         <ul> <li>needles from disposable</li> <li>syringes by hand, and do</li> <li>not bend, break or</li> <li>otherwise</li> <li>manipulate used needles</li> <li>by hand.</li> </ul> </li> </ul>
	<ul> <li>Dispose of syringes, needles, scalpel blades and other sharp objects in appropriate, puncture- resistant containers.</li> </ul>
	<ul> <li>Ensure that puncture- resistant containers for sharps objects are placed as close as possible to the immediate area where the objects are being used ('point of use') to limit the distance between use and disposal, and ensure the containers remain upright at all times. If</li> </ul>
	the sharps container is far, never carry sharps in your hand but place them all in a kidney dish or similar to carry to the sharps container.
	<ul> <li>Ensure that the puncture- resistant containers are securely sealed with a lid and replaced when 3/4 full.</li> </ul>

			<ul> <li>Ensure the containers are placed in an area that is not easily accessible by visitors, particularly children (e.g. containers should not be placed on floors, or on the lower shelves of trolleys in areas where children might gain access).</li> </ul>			
Critical care staff will be aware of any lab testing which cannot be obtained for patients with suspected or proven Ebola	Y	Y		<ul> <li>CCCS<sup>8</sup> p. 25 - Minimize lab tests. Limited menu of blood tests available</li> <li>CCCS<sup>8</sup> p. 37 - "However, the provision of blood products to these patients presents significant technical and patient safety challenges given that no samples from any suspected or confirmed Ebola patients should be sent to the blood bank given that blood bank testing is "open" and therefore not allowed (or safe), until Ebola results come back negative" (see Blood product section further down)</li> <li>PHAC<sup>10</sup> – "No virus culture should be attempted outside of the Public Health Agency of Canada's National Microbiology Containment Level 4 laboratory.</li> <li>For diagnostic or confirmatory services for EVD, liaise with the provincial public health laboratory of your jurisdiction to coordinate with the NML Operations Center Director (OCD) at 1-866-262- 8433"</li> </ul>	One critical care staff MD identified that they had difficulty getting a thick film in a patient suspected of Ebola. Ultimately, the test was performed, but with significant delay. The staff questioned whether some tests were not available in this patient population.	Solution – we have obtained a list of tests that can and cannot be performed. This list is now available in the ICU Ebola binder. A thick film cannot be performed until the patient is confirmed Ebola negative.
Sharps will be safely handled and disposed of	N	N	CDC <sup>12</sup> – "All needles and sharps should be handled with extreme care and disposed in puncture- proof, sealed containers" WHO <sup>5</sup> – Keep a sharps container	PHAC <sup>10</sup> – Limit the use of needles and other sharps as much as possible. Safety engineered devices should be made available	<ul> <li>Participants emphasize some of the measures that should be carried out when handling and disposing of sharps in these cases.</li> <li>Sharps go into red sharps container</li> </ul>	

			nearby when giving injections. Discard single-use needles and syringes immediately after use and directly into the sharps container, without recapping and without passing to another person. Close, seal and send sharps containers for incineration before they are completely full	and used. Used needles should not be recapped; used needles and other used single-use sharp items should be disposed of immediately into designated puncture-resistant containers that are easily accessible at the point-of-use Used needles and other sharp instruments should be handled with care to avoid injuries during disposal."	<ul> <li>Sharps container should be kept close to procedure (limit distance)</li> <li>Never fill container more than half way</li> <li>Do not recap</li> </ul>	
HTMs will consider cardiopulmonary resuscitation in the appropriate setting. HTMs will not perform cardiopulmonary resuscitation in end- stage EVD	N	N		CCCS <sup>®</sup> p.26 – <u>Patients with</u> <u>suspected EBV</u> (not yet confirmed): "Given that most suspect cases of EVD currently presenting in Canada will NOT end up having EVD, <b>life support and</b> <b>resuscitation should be</b> <b>considered</b> if medically indicated in this group, particularly since even if the patients does have EVD they will most likely be in the early stage of the illness, free of multi-organ failure" Considerations for CPR: -rapid automatic external defibrillation -Max 3-4 person team -Meticulous attention to PPE -Adequate team leadership -Limited resources in the room -Organized team outside the room to support the resuscitation team's efforts (drug preparation, etc.)	All participants agreed and no gap was identified.	
HTM will consider dialysis in the appropriate setting and measures will be taken to minimize the contamination risk	Ý	Z	CDC <sup>14</sup> – Recommendations for selection of site and insertion technique for dialysis catheter: "The <b>subclavian</b> site for catheter insertion <b>should be avoided</b> because of the challenges with direct site compression if bleeding occurs. Selection of the internal jugular vs. femoral vein for catheter insertion may depend on patient characteristics and	CCCS <sup>8</sup> p. 40 – "In appropriate settings, dialysis should be considered in the patient with EVD and renal failure. The mode of dialysis, whether intermittent hemodialysis or continuous renal replacement therapy (CRRT), should be individualized based upon the patients status and the treating clinician. However, the use of CRRT will minimize the	Participants agreed that dialysis should be offered in the appropriate clinical context. Specific procedures to decrease the risk of contamination have not been clearly delineated. For example, currently aprons, which are recommended, are not available. CRRT is not available in our unit, only SLED or HD.	

1	1	anaratar proficianay" "I litracaund	need for additional staff to ontar	
		operator proficiency Offrasound		
		guidance should be used (by an	the patient's room ()	
		individual fully trained in this		
		technique) to reduce cannulation		
		attempts and mechanical		
		complications, including arterial		
		puncture. If used, the ultrasound		
		machine should be dedicated to		
		the isolation room until it can be		
		terminally cleaned and		
		disinfected "		
		"Attach closed needleless		
		connector devices to the catheter		
		hubs to reduce blood exposure		
		during antheter connections and		
		during catheter connections and		
		disconnections.		
		CDC – "A nemodialysis/CRRT		
		machine should be dedicated for		
		use on the patient and kept in the		
		isolation room until terminal		
		disinfection procedures are		
		undertaken"		
		CDC <sup>14</sup> – "The Ebola virus should		
		not be able to cross an intact		
		dialyzer membrane. Because a		
		small dialyzer leak might not be		
		apparent, however, dialysis		
		effluent should always be handled		
		with care, and while wearing		
		appropriate PPF to avoid contact		
		and splashes		
		The effluent should be disposed of		
		in the toilet or other dedicated		
		drain in a manner that prevents		
		splashes and can be safely		
		drained into the waste water sewer		
		evetom "		
		system.		
		ir clinically appropriate, consider		
		regional citrate anticoagulation		
		during CRRT to reduce episodes		
		of filter clotting that require		
		manipulation of the dialyzer and/or		
		circuit. Regional citrate		
		anticoagulation for CRRT should		
		be used only if the hospital has a		
		protocol in place and nurses who		

			are trained in the protocol. Consider using the same CRRT machine for hemodialysis of the patient for as long as possible (while renal replacement therapy is needed) to avoid introducing a second dialysis machine" CDC <sup>14</sup> – Provides some guidance on how to decontaminate the dialysis machines after use.			
ECMO will not be offered in patients with proven Ebola	N	N		CCCS <sup>8</sup> p. 40 – not recommended	While all participants agreed that ECMO should not be performed in patients with proven Ebola, it was unclear whether or not ECMO should be offered to patients with suspected Ebola. It was felt by some that ECMO should still be a therapeutic option in patients who screen positive yet are believed to suffer from a disease process other than Ebola.	
HTM will consider using nasogastric (NG) and feeding tube in the appropriate clinical setting and the insertion procedures will minimize the risk of contamination	Y	Ν		CCCS – Should consider if patient is unwell or unable to swallow. Extreme caution with placement of NG tube in patients already experiencing hemorrhagic complications	Participants suggested that NG placement should be considered for management of body fluids. Participants identified that routine NG and feeding tube placement procedures need to be modified to minimize the risk of contamination. For example, participants questioned whether it is necessary to use a two-step placement of feeding tube, which demands two X- rays. In addition, proper positioning is often determined using a stethoscope. At present, an electronic stethoscope is not available. and conventional stethoscope were identified as unsafe.	
The procedure used to handle food will minimize the risk of contamination	N	N			Coordination was noted to be important to deliver food in disposable cutlery containers that will be discarded after use. The dietician confirmed that this process was already in place.	
HTMs will be proficient in the	N	N		CCCS <sup>8</sup> p. 45 – "Sudden Terminal Events	Participants noted that patients with Ebola may experience sudden	

management of sudden terminal events				(Massive hemoptysis, asphyxiation) - Midazolam 5-10mb IV/SC q5min PRN - Deliberate terminal sedation may be important to avoid severe suffering at the time of death. ()"	terminal events such as (massive hemoptysis with asphyxiation). It was suggested that medications to palliate in the event of a terminal catastrophic event be available at the bedside.	
There will be a plan detailing the management of obstetrical patients and newborns.	Y	I/P	WHO <sup>5</sup> p. 27 – Full term deliveries are rare in VHF. As uterine evacuation in pregnant patients appears to lower maternal mortality, it should be considered in confirmed cases given the extremely high maternal and fetal mortality. This procedure must be performed with extreme caution given potential for nosocomial transmission and the risk for inducing maternal hemorrhage. Follow usual clinical guidelines to manage post-partum bleeding.	CCCS <sup>8</sup> p. 37 – Considerations for EBV and Pregnancy: -"()increased severity of illness, high incidence of spontaneous abortion and risk of severe genital bleeding" -"Pregnant women have friable upper airway mucosa, increasing the likelihood of bleeding related to tube insertions and manipulation." -"Fever is likely harmful to the foetus and should be avoided" -"Left lateral positioning is important to prevent the supine hypotension syndrome, in the 2 <sup>nd</sup> half of pregnancy"	Participants noted that the care of pregnant patients is very complex. In addition, the newborn may require resuscitation and/or interhospital transport to the Children Hospital of Eastern Ontario (CHEO)	The department of obstetrics and gynecology is currently performing a needs assessment and developing a plan with ID/IC
Policies and procedures for transfusion of blood products will be clearly documented.	Y	Ν	EMORY <sup>4</sup> p.84 – Support Document 11 "When it is determined that blood products need to be transfused to a SCDU patient, the following protocol will be followed: A. For females of child bearing age, group O negative red blood cells and group AB plasma products will be issued. B. For males and females not of child bearing age, group O positive red blood cells and group AB plasma products will be issued. C. After the <u>first 24 hours</u> , if it is determined that more blood products will be required, the hospital blood bank will be notified to perform a type and screen by manual methods in the SCDU dedicated laboratory. Once a type has been established on two separate occasions, type specific plasma products can be issued. If no passive anti-A or anti-B is detected, type specific red blood	<ul> <li>CCCS<sup>6</sup> p. 37 – "At present many hospitals are not doing phenotyping – but are providing phenotyped units based upon the following approach:         <ul> <li>Unknown to the hospital and never seen by a blood bank elsewhere - issue O neg, Kell neg (so E,C,K neg = 85% of antibodies mitigated)</li> <li>Unknown to the hospital but seen elsewhere - get info from all other hospitals – issue O neg, Kell neg as above + any antibodies matched (e.g., jka, etc.)</li> <li>Known to the hospital – same as above</li> <li>Sickle cell patients – give phenotyped matched based on CBS registry + matched for any antibodies"</li> </ul> </li> <li>CCCS<sup>8</sup> p. 37 – "When transfusion is provided it is recommended that a very cautious 15 min test dose be undertaken at the beginning of</li> </ul>	No transfusion testing is available in patients who are suspected or confirmed to have Ebola at TOH. Further interviews with blood bank and infection control will be required.	

			cells may also be provided.	the transfusion as essentially the final crossmatch will be done in		
There will be a clear process to decide and plan discharge from hospital	Ν	Ν	<ul> <li>CDC<sup>16</sup> - Considerations to take into account when discharging a patient under investigation for EVD without a negative RT-PCR (either not done yet or done with specimen collected less than 72 hours from the start of symptoms):</li> <li>1) In the clinical judgment of the medical team, the PUI's illness no longer appears consistent with Ebola.</li> <li>2) The PUI is afebrile off antipyretics for 24 hours, or there is an alternative explanation for fever.</li> <li>3) All symptoms that are compatible with Ebola (e.g., diarrhea or vomiting) have either resolved or can be accounted for by an alternative diagnosis.</li> <li>4) The PUI has no clinical laboratory results consistent with Ebola, or those that could be consistent with Ebola have been otherwise explained.</li> <li>5) The PUI is able to self-monitor (or to monitor a child, if the PUI is a child) and comply fully with active monitoring and controlled movement.</li> <li>6) There is a plan in place for the PUI to return for medical care if symptoms recur.</li> <li>7) Local and state health departments have been engaged and concur.</li> <li>8) Active monitoring and controlled movement still apply for persons who have had Ebola virus exposures and are under follow-up as contacts for the full 21-day period following their last exposure.</li> </ul>	<ul> <li>CCCS<sup>®</sup> p. 44 – Case by case decision, but two general criteria currently in use are:         <ol> <li>Symptom free &gt; 72 hours</li> </ol> </li> <li>Two consecutive blood samples at least 24 hours apart have been negative for the Ebola virus by PCR</li> <li>PHAC<sup>10</sup> – "Discharge planning (including but not limited to continuation of infection control precautions in the home setting) should be managed on a case-by-case basis in consultation with infectious disease specialists, IPC and PH. Individuals recovering from EVD should either abstain from sexual intercourse or wear condoms for a minimum of 12 weeks, ideally for 15 weeks after the date of symptom onset."</li> </ul>	These decisions would be made jointly with ID specialists	

WHO <sup>°</sup> p. 61-62 –		
Discharge of an alert case is done		
on the following conditions:		
Patients have been reviewed by		
the V/HE clinical management		
the viri clinical management		
team and found not to meet the		
case definition of a suspected		
case, with no epidemiological link		
to:		
<ul> <li>Any suspected or confirmed</li> </ul>		
case		
Have a conclusive diagnosis		
that is not V/HE recognizing		
that is not VHF, recognizing		
that co-infections do occur.		
<ul> <li>Have responded to specific</li> </ul>		
treatment		
<ul> <li>Be in good health condition</li> </ul>		
and able to go back home		
Ũ		
Discharge of VHE-confirmed case		
or suspected cases is based on		
the clinical presentation and the		
the clinical presentation and the		
correct interpretation of the		
laboratory findings. Consider		
discharge when the following		
criteria are met:		
<ul> <li>3 or more days without fever</li> </ul>		
or significant symptom		
(symptoms suggestive of		
ongoing shedding of virus		
include diarrhea, coughing		
blooding) Instruct patients		
thet despite resolution of		
that despite resolution of		
symptoms, viral shedding is		
known to occur in the semen		
of male patients and probably		
breast milk of lactating		
females but this should not		
preclude discharge.		
- AND significant improvement		
in clinical condition		
- AND in good general		
condition		
- AND II IADOIAIOIY lesuing is		
available: negative blood		
PCR for VHF (regardless of		
any other serologic tests) on		
day 3 or later following onset		
of symptoms (if the patient		
had a previously positive		

	blood PCR test, this means a		
	subsequent negative test 48		
	hours from the initial test or		
	for patients with previously		
	blood PCR positive mothers.		
	that are breast feeding, it may		
	he safer to delay discharge		
	until PCP on broast		
	milk turns pogstive as well)		
	If a patient continues to suffer		
	- If a patient continues to suffer		
	symptoms and/or their		
	condition is not improving, but		
	this is not thought to be due		
	to active filovirus disease, 2		
	negative blood PCR tests 48		
	hours apart, with at least one		
	test being done 3 days or		
	more after onset of		
	symptoms, are needed		
	before discharge/referral to a		
	normal ward for further care.		
	Discharge orders/prescriptions:		
	<ul> <li>1 month supply of vitamin</li> </ul>		
	supplements		
	- Nutritional advice		
	Lise condems for 3 months		
	- Ose condonis for 5 months		
	(Indie patients)		
	- Breastreeuing women should		
	stop until FCR testing of		
	breast milk is negative.		
	- Provide a medical certificate		
	to the patient to certify that		
	the patient does not		
	constitute any danger to his		
	family or his neighbors.		
	5		
	WHO <sup>°</sup> – follow-up		
	A system for follow-care should be		
	set up for these patients.		
	Psychological support and		
	follow up should be		
	considered.		

#### I. Ebola Specific Diagnosis and Treatment

•			Documen	t Analysis	Qualitative Data	Proposed solutions
Result	Gap identified	Solution Implemented	International Documents - WHO / CDC / Emory	National, Regional and Local - MOHLTC and TOH - CCCS - Public Health Agencies	Factors to be considered in the development and implementation of solutions	Description of solution, person responsible, timeline to implementation
HTMs will order the most suitable test to diagnose Ebola	Ν	Ν	CDC <sup>17</sup> – "CDC recommends testing for all persons with onset of elevated body temperature or subjective fever within 21 days of having a high-risk exposure such as (See <u>CDC's laboratory testing</u> <u>guidance</u> ): -Percutaneous or mucous membrane exposure or direct skin contact with body fluids of a person with a confirmed or suspected case of EVD without appropriate personal protective equipment (PPE), -Laboratory processing of body fluids of suspected or confirmed EVD cases without appropriate PPE or standard biosafety precautions, or -Participation in funeral rites or other direct exposure to human remains in the geographic area where the outbreak is occurring without appropriate PPE. For persons with a high-risk exposure but without a fever, testing is recommended only if there are other compatible clinical symptoms present and blood work findings are abnormal (i.e., thrombocytopenia <150,000 cells/µL and/or elevated transaminases)." CDC <sup>15</sup> – Timing of testing: "Virus is generally detectable by real-time <u>RT-PCR from 3-10 days</u> <u>after symptoms appear</u> .		ICU physicians indicated that they would rely on Infectious Disease specialists to order and interpret the required tests.	Solution – None required

	udean a summer and a national		
	when a symptomatic patient		
	reports to a healthcare facility and		
	is suspected of having an Ebola		
	exposure. However, if the onset of		
	symptoms is <3 days, a later		
	specimen may be needed to		
	completely rule-out Ebola virus, if		
	the first specimen tests negative		
	$CDC^{16}$ – Important considerations		
	with the PT PCP test for Ebela		
	<ol> <li>A negative RT-PCR test result</li> </ol>		
	for Ebola virus from a blood		
	specimen collected less than 72		
	hours after onset of symptoms		
	does not necessarily rule out		
	Ebola virus infection.		
	2) If the patient is still symptomatic		
	after 72 hours the test should be		
	repeated		
	Tepealeu.		
	2) If the netient has recovered		
	3) If the patient has recovered		
	from the illness that brought them		
	to medical attention, a repeat test		
	is not required.		
	<ol><li>A negative RT-PCR test result</li></ol>		
	for Ebola virus from a blood		
	specimen collected more than 72		
	hours after symptom onset rules		
	out Ebola virus infection.		
	5) Positive Ebola virus RT-PCR		
	results are considered		
	presumptive until confirmed by		
	CDC There will be a clear process		
	to decide and plan discharge from		
	hospital.		
	5		
	WHO ° p. 5-6, 15, Appendix A1 –		
	Standard case definitions or VHF		
	have been developed to identify		
	cases as:		

1				
		<i></i>		
		<u>"Alert"</u>		
		<ul> <li>Definition: patient presenting</li> </ul>		
		with unexplained fever or		
		history of fever (onset less		
		than 3 weeks) AND		
		unexplained bleeding signs		
		(hemorrhagic or purpuric		
		rash, epistaxis, hematemesis,		
		hemoptysis, bloody stools,		
		other hemorrhagic signs)		
		AND no known predisposing		
		factors for hemorrhagic		
		manifestations OR a patient		
		presenting with any fever OR		
		3 more of the following:		
		headache, nausea or		
		vomiting, abdominal pain.		
		generalized or articular pain.		
		loss of appetite, diarrhea.		
		difficulty swallowing, difficulty		
		breathing, intense fatique)		
		AND possible filovirus		
		exposure: unexplained		
		death(s) in the family or close		
		contacts, unexplained (cluster		
		of) serious illness in family or		
		close contacts, provision of		
		care for the seriously ill or		
		handing bodies (caretakers.		
		health workers, those		
		participating in traditional		
		funerals), at risk contact with		
		apes or bats (dead or alive).		
		entry into caves or proximity		
		to fruit trees that host bats		
		"Suspect"		
		Definition: Any person 1)		
		having had contact with a		
		clinical case AND presenting		
		with acute fever (T > 38 C)		
		OR 2) having had contact		
		with a clinical case (suspect.		
		probable, or confirmed) AND		
		presenting with 3 or more of		
		the symptoms below: OR 3)		
		presenting with acute fever		
		AND presenting with 3 or		
		more of the following		
1				

			<ul> <li>concerning symptoms: headache, generalized or articular pain, intense fatigue, nausea or vomiting, loss appetite, diarrhea, abdominal pain, difficulty in swallowing, difficulty in breathing, hiccups, miscarriage OR 4) with unexplained bleeding or miscarriage OR 5) Any explained death</li> <li><u>"Probable"</u></li> <li>Definition: 1) A suspect case that is known to have had contact with a known case (suspect, probable, or confirmed) OR 2) A patient that is, on clinical and/or epidemiological grounds, very likely to have Ebola</li> <li><u>"Confirmed"</u></li> <li>Definition: laboratory testing with positive PCR test for Ebola Once "Alert" cases present to the medical personnel, however, the "alert" label should be discarded and a determination made as to whether the person falls into one of the other categories.</li> </ul>		
Physicians will order and have access to the most appropriate therapy to target EVD	N	N		ICU physicians indicated that they would rely on Infectious Disease specialists to identify and recommend any EVD targeted therapies. Pharmacist did not identify any need at this time given that the current treatment is purely supportive.	

#### J. Critical Care Staffing Issues

			Documen	t Analysis	Qualitative Data	Proposed solutions
Result	Gap identified	Solution Implement	International Documents - WHO / CDC / Emory	National, Regional and Local - MOHLTC and TOH - CCCS - Public Health Agencies	Factors to be considered in the development and implementation of solutions	Description of solution, person responsible, timeline to implementation
There will be sufficient staff available at all times with the required expertise and PPE training to provide patient care and maintain the patient area	Y	<i>I/</i> P	EMORY <sup>4</sup> p.13 – "It is recommended that nurses doff PPE every 4 hours to allow for personal needs and a break. At the highest level of PPE and patient care, 3 nurses will be working in the Unit at one time, in 12-hour shifts. They rotate in 4- hour shifts between the patient room, the anteroom and the nursing desk"	MOHLTC (Oct 30 <sup>th</sup> ) <sup>9</sup> p.6 – "Care to suspect and confirmed cases must be provided by at least two registered nurses at all times. The two nurses do not need to be in the room at the same time and all the time – this depends on the patient care activities and the organization's procedures. In some cases, the second nurse may be better placed outside the patient room in order to provide supplies. These nurses must have no other duties while caring for suspect or confirmed cases." CCCS <sup>8</sup> - Optimal RN to patient ratio = 2:1 CCCS <sup>8</sup> p. 22 – Physical Heat Stress. "() in situations where HCWs must remain in PPE for long periods of time, heat stress is a significant issue and has led some institutions to select the use of powered air purifying respirators (PAPRs)" CCCS <sup>8</sup> p. 47 – "Hospitals should have a plan in place to support HCW caring for EVD patients. If at all possible, resilience training should be provided in advance of staff providing care for EVD patients to potentially protect them from the stress of the situation." CCCS <sup>8</sup> p.21 "Despite the need to minimize the amount of time spent in a patient's room, a HCW must advance be at the reach to suitable.	<ul> <li>Participants proposed that only ICU attendings and critical care fellows would be allowed to manage patients with suspected or proven Ebola. Participants noted that managing patients with Ebola will be time-consuming especially during transfer. They suggested that additional physician staffing might therefore be required to manage other ICU patients.</li> <li>Participants suggested that only experienced RTs and nurses (minimum of 3 years experience) be assigned to patients with suspected or proven Ebola.</li> <li>Staffing requirements must take into consideration the fatigue and stress associated with caring for patients with suspected or confirmed Ebola. This could be particularly problematic for staff wearing PPE. The participants expressed serious concerns that HTM would fail to recognize that they are becoming tired, thus increasing the risk of contamination. They suggested strategies to minimize fatigue including:</li> <li>A minimum of 3:1 nursing/patient ratio for critically ill patients to limit the period of time spent in the room or acting as the spotter. The ratio may need to be increase to 4 or 5:1 depending on the workload.</li> <li>Restricting the responsibility of nurses to their patients with Ebola (i.e., not covering other patients)</li> </ul>	Solution - Minimum 3:1 nursing and possibly dedicated MD currently determining how this would be feasible with given resources/scheduling.
				minimize the amount of time spent in a patient's room, a HCW must always be at the ready to quickly	<ul><li>Ebola (i.e., not covering other patients)</li><li>Not allowing staff that has been</li></ul>	

		1		and an the stanting the second of the stant		L
				enter the patient's room. Given the	up all hight to enter the patient	
				Significant length of time to don	room.	
				PPE in a safe and controlled	A 1:1 physician/patient ratio	
				manner this means that a HCW	(i.e. freeing physician of all	
				must always be dressed in PPE	other responsibilities) during	
				sitting in the warm zone and ready	transport or whenever the	
				to enter into the hot zone at a	physician is called into the	
				moment's notice if the patient	room to manage the patient.	
				requires assistance ()"		
				the O	The need to always have a HTM	
				MOHLTC (Oct 30 <sup>(11</sup> ) <sup>9</sup> p.6 –	fully donned and available to enter	
				"Hospitals should limit the number	the room was questioned by the	
				of HCWs that come into contact	participants.	
				with suspect and confirmed cases,		
				and non-essential personnel "	No concerns with staffing were	
					identified by housekeeping and	
					waste management.	
The roles and	Y	Ν	CDC <sup>11</sup> – "Designate individuals as		The roles and responsibilities of	
responsibilities of			site managers responsible for		HTMs directly caring for these	
HTMs directly or			overseeing the implementation of		patients has not yet been clearly	
indirectly involved in			precautions for healthcare workers		defined.	
the care of patients			and patient safety. A site			
with suspected or			manager's sole responsibility is to			
proven Ebola will be			ensure the safe and effective			
clearly defined,			delivery of Ebola treatment. These			
-			individuals are responsible for all			
			aspects of Ebola infection control			
			including supply monitoring and			
			evaluation with direct observation			
			of care before, during, and after			
			staff enter an isolation and			
			treatment area"			
			Room nurse = "()in charge of all			
			direct patient care, ensuring the			
			quality of all protective practices of			
			personnel entering and exiting the			
			room, waste management and all			
			patient room cleaning"			
			· · · · · · · · · · · · · · · · · · ·			
			Anteroom nurse = "()are			
			utilized as quality control officers.			
			ensuring all protective practices			
			are strictly followed. They are			
			responsible for constantly cleaning			
			after all personnel leaving the			
			patient room; transporting patient			
			room waste through the anteroom			
			and out for processing: and			
			decontaminating all anteroom			

			surfaces, equipment and the locker room. Anteroom nurses are relied upon for charting, supply ordering and stocking."			
			<b>Desk nurse</b> = "()are resources for breaks, food delivery, stocking, supply ordering, retrieving prescriptions, coordinating various patient care orders and managing anything else that is needed"			
			<b>EMORY<sup>4</sup> General statement for</b> <b>nursing roles</b> = "In an effort to minimize the number of health care workers potentially exposed to patients isolated in the Unit, nursing personnel will perform all phlebotomist functions, obtain all cultures, perform electrocardiograms (ECG), run dialysis and ventilator management as needed, assist with patient physical therapy and use any other skill sets as necessary. Nursing staff will also perform all duties normally associated with nurse technician, environmental services and unit clerk roles"			
			WHO <sup>5</sup> p. 46 – Members of staff will not move freely between the isolation areas and other clinical areas during the outbreak.			
HTMs who have cared for patients with Ebola will monitor themselves for signs of infection	Y	N		CCCS <sup>8</sup> p. 46-47 – "There are no restrictions (e.g. quarantine) placed upon HCWs who care for EVD patients who have not experienced a noted breach in infection control procedures. However, HCWs caring for EVD patients are recommended to self- monitor for fever, for full details on current guidance please refer to <sup>20</sup> "	<ul> <li>Participants were unclear on the monitoring of HTMs who have worked with patients with Ebola.</li> <li>They raised the following questions:</li> <li>Should they only monitor temperature or other symptoms such as diarrhea (as is being recommended by Emory)?</li> <li>Who would oversee the monitoring?</li> </ul>	

#### K. Visitation and Contacts

			Documen	t Analysis	Qualitative Data	Proposed solutions
Result	Gap identified	Solution Implement	International Documents - WHO / CDC / Emory	National, Regional and Local - MOHLTC and TOH - CCCS - Public Health Agencies	Factors to be considered in the development and implementation of solutions	Description of solution, person responsible, timeline to implementation
Visitation rights will be clearly defined	N	N	<ul> <li>CDC <sup>11</sup>- "restrict non-essential personnel and visitors from the patient care area"</li> <li>CDC <sup>12</sup> - "Avoid entry of visitors into the patient's room"</li> <li>CDC <sup>12</sup> - "Establish procedures for monitoring managing and training visitors"</li> <li>Schedule visits in order to plan for: 1) Screening for EVD in visitors 2) Ability to comply with precautions 3) Instruction on proper PPE use</li> <li>WHO<sup>5</sup> p. 46 - Assure restricted access. Stopping visitor access to the patient is preferred. If this is not possible, limit their number to those who are necessary for the patient's care and well-being (i.e. parent for a sick child). The visitor should keep a minimum distance of 3 meters.</li> <li>WHO<sup>5</sup> p. 46 - Use signage and other communications to alert restrictions of visitors.</li> <li>WHO<sup>5</sup> p. 46 - All visitors must use PPE and perform hand hygiene. Provide them with the appropriate instructions prior to entering the room.</li> </ul>	MOHLTC (Oct 30 <sup>th</sup> ) <sup>9</sup> p.6 – " visitors must be excluded from entry to the patient's room" CCCS <sup>8</sup> p.21 – Family or visitors should not enter the room CCCS <sup>8</sup> p.21 – "Arrangements should be made to allow family members to communicate from outside the unit (or hospital) with the patient. Internet based video chat technologies can be very useful for this"	<ul> <li>Participants had the following questions:</li> <li>Should visitors be allowed?</li> <li>If so, who would train them on the use of PPE?</li> <li>Who would determine if they are proficient?</li> <li>What actions would be taken if they are not compliant with the PPE procedures?</li> <li>It was noted that these questions may not be relevant at present, given that the MOHLTC has stated that visitors were not allowed</li> </ul>	
Support will be provided to patients and their family members	Y	N	WHO° p. 43, section 4 – Psychological support for the patient and the family are very important. Anxiety and fear are normal given the high mortality rate for confirmed VHF. Ideally, a psychologist or nurse skilled in	CCCS° p. 47 – "Hospitals should plan to provide support to both patients and their families. This includes ensuring that processes are in place to allow communication and visitation between patients and families"	Has not yet been explored with participants	

			providing psychological support should be involved from the outset, but providing psychological care in PEE can be uncomfortable and difficult.	CCCS <sup>8</sup> p. 47 – Offer support with services like Social Work, Chaplaincy and Psychiatry. CCCS <sup>8</sup> p. 47 – "Given the concerns regarding transmission and desire to minimize patient exposure leveraging technologies such as internet video chat should be considered and the necessary IT infrastructure should be provided."		
There will be a clear process on how to manage anyone who has had unprotected contact with a patient with suspected or confirmed Ebola	Y	N		PHAC <sup>18</sup> – "Quarantine is <b>not recommended</b> for close contacts of a confirmed or probable case. Active daily monitoring of close contacts for fever and other symptoms should be conducted by public health staff for the duration of the monitoring period (i.e. 21 days from the last possible exposure or upon receipt of negative testing for the probable case with whom this person was in contact). If necessary, teach the individual how to take their temperature accurately and provide a thermometer to them if they do not have access to one. For the 21 days following the last possible exposure, or until the probable case with whom this person was in contact no longer meets the case definition (i.e. the laboratory investigation has ruled out Ebola virus infection), advise the close contact to: Take (orally) and record their temperature twice daily and report any reading ≥ 38.6°C (101.5°F) to public health immediately (as opposed to waiting for public health to contact them as part of active daily monitoring). Refrain from taking any antipyretic	<ul> <li>Participants noted that family members or others who have been in close contact with a patient with Ebola could also be infected.</li> <li>Participants raised the following questions: <ul> <li>What actions should be taken to safely manage these contacts?</li> </ul> </li> <li>Who will trace the contacts and decide whether quarantine is required?</li> <li>Does ICU staff play a role in managing close patient contact?</li> </ul>	

			medication during the monitoring period if possible. Self-monitor for the appearance of any other early symptoms of EVD including severe headache, muscle pain, malaise, sore throat, vomiting, diarrhea and rash. Should symptoms develop, self- isolate as quickly as possible and contact the local public health authority immediately for further direction. If symptoms consistent with EVD (including an oral temperature reading ≥ 38.6°C (101.5°F)) develop in the close contact, public health should manage the individual as a probable case." PHAC <sup>18</sup> – "Close contacts of <i>confirmed and</i> <i>probable</i> cases should not travel outside of their city of residence during the monitoring period in order to facilitate daily contact with		
			conducting active daily monitoring as well as access to health care in		
			an appropriate setting should it be required."		
There will be a clear process on how to screen visitors to the ICU and manage any visitor who is found to be positive.	Y	N		Participants questioned whether all visitors to the ICU would be screened and if so how? It was noted that the current plan is to inform visitors that self-screening should be performed before entering the ICU.	
				It was unclear if this plan would change if a patient with suspected or confirmed Ebola is admitted in the ICU. Some participants recommended that under these	
				screened before entering the ICU. Participants also questioned who would perform the screening and whether the person performing the screening should be wearing PPE.	
There will be a clear	Y	Ν		The participants questioned what	

process on how to			procedure to follow if a visitor was	
manage any visitor			found to be screen positive. For	
who is screen positive			example, do ICU clerks need to	
			know the steps to take if a visitor	
			self-screens positive?	

## L. Waste management, Environmental Cleaning, Management of Linens

			Document	t Analysis	Qualitative Data	Proposed solutions
Result	Gap identified	Solution Implement	International Documents - WHO / CDC / Emory	National, Regional and Local - MOHLTC and TOH - CCCS - Public Health Agencies	Factors to be considered in the development and implementation of solutions	Description of solution, person responsible, timeline to implementation
Waste will be safely removed from the room	Y	I/P	EMORY <sup>4</sup> p.50-52 – (Appendix 9: Waste Management Process from High Containment Hospital Suite to Autoclave) Separated in 6 sections: 1) IN PATIENT ROOM 2) IN THE ANTEROOM 3) AUTOCLAVING 4) POST AUTOCLAVE 5) VALIDATION OF AUTOCLAVE CYCLE 6) TRANSPORT CDC <sup>19</sup> – Management of disposable materials (e.g., any single-use PPE, cleaning cloths, wipes, single-use microfiber cloths, linens, food service) and linens, privacy curtains, and other textiles after use: "These materials should be placed in leak-proof containment and discarded appropriately. To minimize contamination of the exterior of the waste bag, place this bag in a rigid waste receptacle designed for this use. Incineration or autoclaving as a waste treatment process is effective in eliminating viral infectivity and provides waste minimization."	<ul> <li>PHAC<sup>10</sup> – "Biomedical waste (e.g., sponges, dressings and surgical drapes soaked with blood or secretions) should be contained in impervious waste-holding bags or double bags according to municipal/regional regulations.</li> <li>Blood, suctioned fluids, excretions and secretions should be disposed of in a sanitary sewer or septic system according to municipal/regional regulations."</li> <li>TOH – Waste protocol for suspect/confirmed Ebola virus (Sept 2014): Nurse or designate will dispose all biomedical (blood and/or body fluid) waste from a suspect/confirmed Ebola patient into RED single use red containers AND label with a white UN2814 sticker. Nurse or designate will dispose all regular waste items (items NOT dripping with blood and/or body fluids) into the regular black bag trash. Nurse or designate will immediately place a call to a Housekeeping supervisor to have a trained staff member sent to remove the waste. Please ensure to identify to</li> </ul>	All disposable waste must be placed in red hazardous waste buckets. Participants had concerns with practical aspects of waste removal from the room, including how to seal the buckets and how to move them safely from inside to outside the room, given that the outer surface of the bucket is assumed to be contaminated. Further concerns were raised that the buckets were too small and that the process of removing body fluids, including suction disposal, was unclear.	Solution – Numerous walkthroughs have been performed. The waste management team has also acquired larger plastic blue drums for disposal of waste, which are also easier to seal and do not require a machine. They have developed a process for removal with a drum dolly. The drum will be disinfected twice and markers have been placed on the drums to help HTMs keep track of the disinfection process. Next step is to perform a walk-through with nursing staff and waste management with the new drum.

			WHO <sup>5</sup> p. 50 – Waste should be segregated at point of generation to enable appropriate and safe handling. Sharp objects (e.g., Needles, syringes, glass articles) and tubing that has been in contact with blood or body fluids should be placed inside puncture resistant waste containers. These should be located as close as practical to the patient care area where the items are used. Collect all solid, non-sharp infectious waste using leak-proof waste bags and covered bins.	the supervisor that the waste is from a suspect/confirmed Ebola patient. Nurse or designate will seal and wipe down outside of bags/containers with a hospital grade disinfectant before bags/containers leave the patient room. Nurse or designate will pass bags/ containers out the patient room door to the housekeeping waste porter (wearing gloves) in the anteroom.		
Processes will be in place to handle spills.	Y	N	<ul> <li>against the body</li> <li>CDC<sup>19</sup> – "CDC guidelines recommend removal of bulk spill matter, cleaning the site, and then disinfecting the site. For large spills, a chemical disinfectant with sufficient potency is needed to overcome the tendency of proteins in blood and other body substances to neutralize the disinfectant's active ingredient ()"</li> <li>EMORY<sup>4</sup> p.44 – Spill Cleanup protocol Alert team.</li> <li>Assist patient.</li> <li>Establish a spill parameter.</li> <li>Visual check of PPE and clean any visible contamination Pour disinfectant on clean towel to establish chemical mat* near spill.</li> <li>Remove one bootie, then step onto newly created chemical mat*; repeat with second bootie.</li> <li>Sanitize gloves.</li> <li>Sanitize gloves.</li> <li>Sanitize gloves.</li> <li>Soak clean towel in disinfectant.</li> <li>Cover spill outside-in with bathroom towel.</li> </ul>		Standard practice with spill kits and Clorox was identified as the practice plan. Interviews with HTMs, including housekeeping, identified that the process of spill clean up needs to be established, including clarifying the roles and responsibilities of HTMs, (physicians, nurses housekeeping, etc.).	

			Allow for appropriate contact time			
			(10 minutes)			
			Clean up spill from outside-in			
			Sanitize gloves			
			Bomovo outor diovos			
			Den new outer gloves.			
			Don new outer gloves.			
			Nop area, placing wipes in red			
			bag.			
			Sanitize gloves.			
			Remove one bootie, then step			
			onto newly created chemical mat*;			
			repeat with second bootie.			
			Sanitize gloves.			
			Remove outer gloves.			
			Don outer gloves then booties			
			Follow Waste Management for			
			Patient Room protocol.			
Processes will be in	Ν	Ν	CDC <sup>11</sup> – "Perform regular cleaning	CCCS <sup>8</sup> p.21 – "() even all	Participants noted that the anteroom	Solution – Housekeeping is
place to clean and			and disinfection of patient care	cleaning of the room whilst the	should be cleaned more frequently	developing a protocol
disinfect surface			area surfaces, even absent visible	patient is present, should be		1 0 1
areas			contamination. This should be	conducted by core nurse and	The practice at TOH includes	
			performed only by nurses or	physician team"	experienced environmental services	
			physicians as part of patient care	<u> </u>	staff performing cleaning not MDs	
			activities in order to limit the		or nurses. This is in keeping with	
			number of additional healthcare	MOHLTC (Oct $30^{\text{th}})^9$ n 9 –	the MOHLTC, which is contradicted	
			workers who enter the room"	"Experienced environmental	by the CDC and CCCS	
				services staff trained in OHS and		
			<b>CDC</b> <sup>19</sup> – "Daily cleaning and	IPAC practices and use of PPF	Concerns were raised by	
			disinfection of hard non-porous	should be assigned to perform	physicians nurses housekeeping	
			surfaces (e.g. high-touch	these tasks "	and waste management about the	
			surfaces such as bed rails and		possibility of MDs or nurses	
			over hed tables, housekeeping	MOHLTC (Oct $30^{\text{th}})^9$ n 9 – "All	performing environmental cleaning	
			surfaces such as floors and	used cleaning wines/cloths should	as they have not been trained to	
			counters) should be done $\frac{4}{2}$ Before	be disposed of in leak-proof color-	perform these duties and hence if	
			disinfecting a surface cleaning	coded bags/containers_doubled	they were assigned this task it may	
			should be performed. In contrast	bagged and the outer container	result in inadequate cleaning and/or	
		1	to disinfection where products with	wined with disinfectant before	contamination	
			specific claims are used any	removal from the room		
			alconing product can be used for	The frequency of cleaning		
			cleaning product can be used for	should be based on the lovel of		
			disinfocting products according to	should be based on the level of		
		1	label instructions. Check the	other body fluids, and at least		
		1	disinfoctant's label for apositio	daily Housekooping aquipment		
			instructions for inactivation of any	should be dispessible or remain in		
			of the nen enveloped virues	the room for the duration of the		
				netiont's admission		
		1		Linon discharge of the nations at		
			auenovirus, poliovirus) ()	discontinuation of processions		
		1	CDC <sup>19</sup> "Uso a U.S	dischargo/torminal algoning of the		
			Environmental Distantian Agents	room abould follow the		
			Environmental Protection Agency	room should follow the		

- T	(EDA) registered beenitel	recommended practice for	
	(EPA)-registered hospital	recommended practice for	
	disinfectant with a label claim for a	discharge/terminal cleaning of a	
	non-enveloped virus (e.g.,	room on Contact/Droplet	
	norovirus, rotavirus, adenovirus,	Precautions. In addition to routine	
	poliovirus) to disinfect	cleaning:	
	environmental surfaces in rooms	<ul> <li>All dirty/used items (e.g.,</li> </ul>	
	of patients with suspected or	suction containers, disposable	
	confirmed Ebola virus	items) should be	
	infection"WHO <sup>5</sup> – Use the same	removed/discarded	
	PPE for disinfecting the	<ul> <li>Curtains (privacy window)</li> </ul>	
	environment	shower) should be disposed of	
		before starting to clean the	
	WHO <sup>7</sup> n 8 – Cleaning process	room	
	Clean contaminated	<ul> <li>Eventhing in the room that</li> </ul>	
	onvironment/objects as seen as	cannot be cleaned should be	
	environment/objects as soon as	disserted	
	detergente/disinfectente (ov. 0.5%)	UISCAIDEU	
	detergents/disinfectants (ex. 0.5%	<ul> <li>Fresh cloths, mop, supplies and</li> </ul>	
	chlorine solution or a solution	solutions should be used to	
	containing 5000 ppm available	clean the room	
	free chlorine. Application of	<ul> <li>Several cloths should be used</li> </ul>	
	disinfectants should be preceded	to clean the room	
	by cleaning to prevent inactivation	<ul> <li>Each cloth should be used one</li> </ul>	
	of disinfectants by organic matter.	time only	
	Change cleaning solutions (daily)	<ul> <li><u>Cloths should not be dipped</u></li> </ul>	
	and refresh equipment frequently	back into disinfectant solution	
	while being used during the fay,	after use	
	as they will quickly become		
	contaminated. (Annex 6,		
	preparing chlorine based	<ul> <li>All surfaces should be cleaned</li> </ul>	
	solutions)	and disinfected allowing for the	
	Clean floors and horizontal work	appropriate contact time with	
	surfaces at least once a day with	the disinfectant as per	
	clean water and detergent	manufacturer's	
	Surfaces should dry paturally	recommendations	
	boforo uso	<ul> <li>All housekeeping equipment</li> </ul>	
	belore use.	should be cleaned and	
	EMORV <sup>4</sup> p 14 "The purging	decontaminated before putting	
	teem is reasonable for all	it back into general use "	
	cleaning within the entercomend	-	
	notiont rooms"	PHAC <sup>10</sup> – "All horizontal and	
	patient rooms	frequently touched surfaces	
		should be cleaned at least twice	
		daily and when soiled.	
		Surfaces that are likely to be	
		touched and/or used frequently	
		should be cleaned and disinfected	
		on a more frequent schedule. This	
		includes surfaces that are in close	
		proximity to the patient (e a	
		bedrails bedside/over-bed tables	
		call bells) and frequently touched	
		sall solid, and hequointy touoned	

					surfaces in the patient care environment, such as door knobs, surfaces in the patient's bathroom."		
	Measures will be taken to avoid contamination and facilitate cleaning.	Y	Ν	CDC <sup>19</sup> – "Avoid contamination of reusable porous surfaces that cannot be made single use. Use only a mattress and pillow with plastic or other covering <u>that fluid</u> cannot get through. Do not place patients with suspected or confirmed Ebola virus infection in carpeted rooms and remove all upholstered furniture and decorative curtains from patient rooms before use"		Participants expressed concerns that disinfecting the hospital bed and/or stretcher might be difficult. Many HTMs recommended covering the stretcher in plastic prior to transporting the patient. HTMs also stressed the importance of ensuring the mattress did not have any rips, tears or worn out spots. Participants suggested that If grossly contaminated, the mattress should be disposed of.	
				CDC – "Routine cleaning of the PPE doffing area should be performed at least once per day and after the doffing of grossly contaminated PPE. Cleaning should be performed by a HCW wearing clean PPE"			
				<u>WHO</u> <sup>7</sup> – Cleaning with a moistened cloth helps to avoid contaminating the air and other surfaces with air-borne particles.			
				Cleaning should always be carried out from "clean" areas to "dirty" areas in order to avoid contaminant transfer. Do not spray the disinfectant.			
	There will be a clear process in place to handle and clean used linen	Y	Y	<ul> <li>WHO' p.9 –</li> <li>Linen that has been used on patients can be heavily contaminated with body fluids (e.g. blood, vomit) and splashes may result during handling. When handling soiled linen from patients, use gloves, impermeable gown, closed shoes (e.g., boots) and facial protection (mask and goggle or face</li> </ul>	<ul> <li>PHAC<sup>10</sup> – "Patient bed linen should be changed regularly and when soiled, upon discontinuation of precautions and following patient discharge.</li> <li>Soiled linen should be placed in a no-touch receptacle at the point- of-use.</li> <li>Soiled linen should be</li> </ul>	Many concerns were voiced about the processing of linens. Participants expressed concerns that the plan to perform regular processing of linens could contaminate cleaning staff or others.	Solution – Meetings have been held with housekeeping, waste management and infection control. The plan for linens has been changed. At this time, all linens will be disposed of in the waste buckets and destroyed.

	1	
shield).	handled with minimum	
<ul> <li>Soiled linen should be placed</li> </ul>	agitation to avoid	
in clearly labeled, leak-proof	contamination of air,	
bags or buckets at the site of	surfaces and persons.	
use and the container	<ul> <li>Heavily soiled linen</li> </ul>	
surfaces should be	should be discarded	
disinfected (using an	inte a na tauch garbaga	
effective disinfectant) before		
removal from the isolation	receptacle at the point-	
solid excrement such as	of-use.hand hygiene	
faeces or vomit scrane off	should be performed	
carefully using a flat firm	after handling soiled	
object and flush it down the	linen"	
toilet or in the sluice before		
linen is placed in its		
container. If the linen is		
transported out of the patient		
room/area for this procedure		
it should be put in a separate		
container – it should never		
be carried against the body.		
<ul> <li>Linen should be then</li> </ul>		
transported directly to the		
laundry area in its container		
and laundered promptly with		
<ul> <li>For low-temperature</li> </ul>		
laundering, wasn linen with		
detergent and water, rinse		
chloring solution (a solution		
containing 500 ppm available		
free chlorine) for		
approximately 30 minutes		
Linen should then be dried		
according to routine		
standards and procedures.		
Washing contaminated linen		
by hand should be		
discouraged. However, if		
washing machines are not		
available or power is not		
ensured, take the soiled linen		
out of the container and		
empty it into a large drum		
container of hot water and		
soap. Soak the linen in this		
urum and make sure it is		

1						1
			totally covered with water.			
			Use a stick to stir; then throw			
			out the water and refill the			
			orum with clean water and			
			add chlorine 0,1% (a solution			
			containing 1 000 ppm			
			available free chiofine) and			
			allow to soak for 10 – 15			
			minutes. Remove the inten			
			water Remove excess water			
			and spread out to dry Avoid			
			as much splashing as			
			nossible			
			<ul> <li>If cofe cleaning and</li> </ul>			
			<ul> <li>If sale cleaning and disinfection of boovily solled</li> </ul>			
			lipon is not possible or			
			reliable, it may be prudent to			
			burn the linen to avoid any			
			unnecessary risks to			
			individuals handling these			
			items.			
			EMORY <sup>4</sup> p.28 – "For patients who			
			are felt to be infected with			
			smallpox or VHF, all linen will be			
			placed in biohazard, autoclavable			
			bags. Bagged soiled linen bags			
			are considered full when 3/4 full."			
			<b>000</b> <sup>19</sup> " <b>T</b>			
			CDC <sup>10</sup> – "To reduce exposure			
			among staff to potentially			
			contaminated textiles (cloth			
			products) while laundering,			
			discard all linens, non-fluid-			
			mattrosson and toxtile privacy			
			curtains into the waste stream and			
			disposed of appropriately"			
Processes will be in	Y	N	$EMORY^4$ n 53 – Annendix 10	<b>PHAC</b> <sup>10</sup> – "There are no	HTMs were unclear about the	I I
place to clean and		IN I	Emoret plos - Appendix 10	indications for the use of	process to clean and disinfect non-	
disinfect non			"1) In the patient room the	disposable dishes/cutlery except	disposable equipment such as the	
disposable equipment			patient's nurse should cleanse the	in the circumstance of non-	central line tray or the bag-valve-	
and a second of a building			contaminated equipment with	functioning dishwashing	mask apparatus.	
			disinfectant designated by the	equipment."		
			hospital.		The manager of decontamination	
			2) Both the patient room nurse		was identified as a key stakeholder	
			and the anteroom nurse are to		who will need to be interviewed.	
			create disinfectant mats with			
			disposable pads and the			

	disinfectant (200 mL of the		
	solution to 400 mL of water) from		
	the patient's doorway to the		
	storage destination		
	2) The reem pures will then		
	3) The foom hurse will then		
	roll/hand off the unofficial cleaned		
	equipment to the anteroom nurse,		
	where he/she will clean equipment		
	again with disinfectant while in full		
	PPF similar to Waste		
	Management		
	4) Cover equipment with plastic		
	4) Cover equipment with plastic		
	bag and label as dirty so that it will		
	be further decontaminated with		
	vaporized hydrogen peroxide.		
	Roll/hand off equipment to		
	resource nurse outside of		
	anteroom and store in designated		
	dirty storage area. The resource		
	nurse outside the room should		
	wear gown, gloves, bootles and		
	mask with face shield.		
	5) The resource nurse outside of		
	the room doffs PPE per SOP		
	protocol. Anteroom nurse		
	removes PAPR Hood and sets		
	aside "		
	"Ousternary Ammonium		
	Qualernary Ammonium		
	Compound Mat Procedure		
	-Mats will be changed every day		
	at the beginning of the morning		
	by the 7A-7P nurse.		
	-To change, remove tape and		
	discard both tape and mat in the		
	trash		
	-Replace mat with the new fabric		
	chuck had and tane down with 2-		
	inch silk topo		
	Min OODer Laftha must are and		
	-MIX 200mL of the quaternary		
	ammonium compound with 400		
	mL of water and pour on the		
	mat.		
	-The non-diluted compound can		
	cause the floor to become sticky:		
	if this occurs use water to dilute		
	the solution on the floor and mon		
	une solution on the hoor and hop		
	unui the libor is no longer sticky.		
	-Dilute spills of the		
	compound with water as soon as		

	possible, as the quaternary ammonium compound will erode the floors. "		

## M. Post mortem

			Documen	t Analysis	Qualitative Data	Proposed solutions
Result	Gap identified	Solution Implement	International Documents - WHO / CDC / Emory	National, Regional and Local - MOHLTC and TOH - CCCS - Public Health Agencies	Factors to be considered in the development and implementation of solutions	Description of solution, person responsible, timeline to implementation
There will be a clear process in place to handle a deceased patient	Y	P	<ul> <li>CDC<sup>20</sup> – "Autopsies on patients who died of Ebola should be avoided"</li> <li>CDC<sup>20</sup> – Post Mortem Preparation:         <ol> <li>Preparation of the body</li> <li>Wrapped in a plastic shroud at the site of death (avoid contamination of external layer of shroud)</li> <li>Leave endotracheal tube and/or central lines in the patient</li> <li>Do not clean the body</li> <li>After wrapping, the body should be placed in a leak-proof plastic bag of a minimal thickness of 150 µm thick and zippered shut.</li> </ol> </li> <li>Thereafter, the bagged body should be placed in another plastic bag of a minimal thickness of 150 µm thick and zippered shut.</li> <li>Surface decontamination -Before transport to the morgue, decontamination of the outer surface of the corpse-containing body bags.</li> <li>Once the patient's body leaves the room, clean room and non-disposable equipment as per recommendations.</li> <li>CDC<sup>20</sup> – <u>Transport of remains</u>-Should be coordinated with</li> </ul>	<ul> <li>PHAC<sup>10</sup> – Medical devices (i.e., intravenous catheters, urinary catheter, or endotracheal tubes) may be left in place.</li> <li>At the site of the death, the body should be wrapped in a plastic shroud. Care should be taken to prevent the contamination of the exterior surface of the shroud. A leak-proof body bag should be used over the shroud. Once closed the body bag should not be re-opened.</li> <li>Perform surface decontamination of the outer bag by removing visible soil on outer surfaces with a broad-spectrum disinfectant, in according to the manufacturer's instruction.</li> <li>Handling of Human remains should be kept to a minimum (e.g., no autopsies unless necessary, no embalming, and no post-mortem care).</li> <li>Post-mortem examinations and human remains handling should be in accordance with federal and provincial/territorial regulations."</li> </ul>	Participants identified that no process is currently in place to handle a patient who has died from Ebola.	Solution – Infection control is in the process of finalizing the process and documents

	relevant regional and local		
	authorities		
	$100^7$ m 40. The headling of		
	WHO p. 12 – The handling of		
	human remains should be kept to		
	a minimum. The following		
	recommendations should be		
	adhered to in principle, but may		
	nood some adaptation to take		
	need some adaptation to take		
	account of cultural and religious		
	concerns:		
	<ul> <li>Wear PPE (same as that</li> </ul>		
	used for patient care) when		
	handling the remains.		
	<ul> <li>Plug the natural orifices</li> </ul>		
	Place the bedy in a double		
	- Flace the body in a double		
	bag, wipe over the surface of		
	each body bag with a suitable		
	disinfectant (e.g. 0.5%		
	chlorine solution) and seal		
	and label with the indication		
	of highly infectious material		
	Immediately move the body		
	to the mortuary		
	DDE als available a service al		
	- PPE should be removed		
	immediately after and hand		
	hygiene before and after.		
	<ul> <li>Remains should not be</li> </ul>		
	spraved, washed or		
	embalmed. Any practice of		
	washing the remains in		
	proparation for "cloan buriels"		
	preparation for clean buildis		
	should be discouraged.		
	<ul> <li>Only trained personnel</li> </ul>		
	should handle remains during		
	the outbreak.		
	<ul> <li>PPE is not required for</li> </ul>		
	individuals driving or riding a		
	vehicle to transport or collect		
	human remains provided the		
	drivers or riders will not be		
	bondling a dead bady of a		
	nandling a dead body of a		
	suspected or confirmed case		
	of HF.		

## N. Conflict resolution

			Documen	t Analysis	Qualitative Data	Proposed solutions
Result	Gap identified	Solution Implement	International Documents - WHO / CDC / Emory	National, Regional and Local - MOHLTC and TOH - CCCS - Public Health Agencies	Factors to be considered in the development and implementation of solutions	Description of solution, person responsible, timeline to implementation
There will be a clear process in place to respond to family members/visitors who refuses to cooperate with the established policies	Y	N			Participants questioned who has authority if a family member refuses to cooperate (e.g. if a family refuses to follow the required procedures for contacts or tries to enter the patient room).	
There will be a clear process in place to respond to patients who are uncooperative and/or aggressive.	Y	N	WH0 <sup>5</sup> p. 16 – Educate the patient if conscious and cooperative: Educated the patient on what will happen next (once the case is identified as probable or confirmed). Explain the reasons for the isolation/holding. Explain the procedures you are following with respect to controlling transmission to the family, health workers and the community Educate the patient on respiratory hygiene. Give the patient a surgical mask and make sure he/she understands how to use it.		HTMs wanted to know what measures should be taken in the event that a patient does not cooperate or becomes aggressive. Participants envisioned scenarios where a patient could become angry, scared, or delirious and either refuse to go into isolation or attempt to leave the ICU. The safest practice to prevent contamination and care for the patient was not clear. Usual practice of calling a Code White, where security would come to assist, was described as problematic as it could put more HTMs at risk.	

## O. Communication

			Document	t Analysis	Qualitative Data	Proposed solutions
Result	Gap identified	Solution Implement	International Documents - WHO / CDC / Emory	National, Regional and Local - MOHLTC and TOH - CCCS - Public Health Agencies	Factors to be considered in the development and implementation of solutions	Description of solution, person responsible, timeline to implementation
There will be a clear process of communication to ensure that hospital and departmental leaders collaborate	N	Z			The Ebola Core Group has been established and they are meeting regularly.	
There will be a clear	Y	I/P			Gaps were identified in	The following solutions have

process of communication, which ensures that HTMs are well informed and up to date	Y	I/P		communication with front line HTMs. Many HTMs felt they were either misinformed or poorly informed regarding the preparedness planning. It was highlighted that the dissemination of information on Ebola preparedness is particularly complex given that the guidelines and processes are changing rapidly. Some participants believed that lack of information might have added to HTMs anxiety. Some participants identified that they were drowning in information yet still felt misinformed. Suggestions were made to have a central location for all documents and email notification when important updates were made. Simple links included in the email could ease access to pertinent information. Meeting with HTMs to ensure they have up to date information was emphasized. Participants suggested that	<ul> <li>been implemented:</li> <li>Open forums have been held for all HTMs by ID and infection control</li> <li>Grand rounds has been held with ICU staff</li> <li>NA team has met with ICU physicians and nurses at their respective staff meeting</li> <li>HTMs have been invited to meet with NA team members and these individuals have made themselves available during the day.</li> <li>In Progress</li> <li>Creating of a central location for information is being established in the ICU</li> <li>Need to meet with RTs? Other HTMs?</li> </ul>
be established with other institutions designated as Ebola Centers		WF		communication and collaboration be established with other centers, such as Toronto.	Toronto,

#### LIST OF ABBREVIATIONS:

AGP – Aerosol-Generating Procedure BiPAP - Bi-level Positive Airway Pressure CAO – Chief Administration Officer CCCS - Canadian Critical Care Society CDC - Center for Disease Control and Prevention CF - Care Facilitator CXR – Chest X-Ray Emory – Emory Healthcare ED – Emergency Department EKG - Electrocardiogram ER – Emergency Room EVD – Ebola Virus Disease HCP - Health Care Provider HCW – Health Care Worker HTM – Hospital Team Member ICU – Intensive Care Unit ID – Infectious Disease IPAC – Infection Prevention and Control MOHLTC - The province of Ontario's Ministry Of Health and Long-Term Care NA – Needs Assessment NG - Nasogastric NIV - Non-Invasive Ventilation OB GYN – Obstetrics Gynecology PAPR – Powered Air Purifying Respirator PCR – Polymerase Chain Reaction PHAC – Public Health Agency of Canada PHO – Public Health Ontario PPE – Personal Protective Equipment PPV - Positive Pressure Ventilation RACE team - Rapid Assessment of Critical Events team TOH - The Ottawa Hospital VHF - Viral Hemorrhagic Fever WHO – World Health Organization

WT – Walk-through

#### REFERENCES

- 1. Services USDOHAH, Centers for Disease Control and Prevention. Checklist for Patients Being Evaluated for Ebola Virus Disease (EVD) in the United States. 2014:1–1. Available at: http://www.cdc.gov/vhf/ebola/pdf/checklist-patients-evaluated-us-evd.pdf. Accessed November 6, 2014.
- 2. CDC. Ebola Virus Disease (Ebola). 2014:1–1. Available at: http://www.cdc.gov/vhf/ebola/pdf/ebola-algorithm.pdf. Accessed November 3, 2014.
- 3. *Case Definition for Ebola Virus Disease (EVD).* Center for Disease Control and Prevention Available at: http://www.cdc.gov/vhf/ebola/hcp/case-definition.html. Accessed October 28, 2014.
- 4. *Emory Healthcare Ebola Preparedness Protocols*. Emory Healthcare Available at: http://www.emoryhealthcare.org/ebola-protocol/ehc-message.html. Accessed October 24, 2014.
- 5. WHO. Clinical management of patients with viral haemorrhagic fever. 2014:1–113. Available at: http://www.who.int/csr/resources/publications/clinical-management-patients/en/. Accessed October 21, 2014.
- Ontario PH, ed. Initial assessment and management of the returning traveller from countries/areas affected by Ebola virus disease: Primary Care Providers. 2014:1–6. Available at: http://www.publichealthontario.ca/en/eRepository/EVD\_screening\_tool\_primary\_health\_care\_providers.pdf. Accessed October 23, 2014.
- 7. WHO. Interim Infection Prevention and Control Guidance for Care of Patients with Suspected or Confirmed Filovirus Haemorrhagic Fever in Health-Care Settings, with Focus on Ebola. 2014:1–24. Available at: http://www.who.int/csr/resources/publications/ebola/filovirus\_infection\_control/en/. Accessed October 21, 2014.
- CCCS, AMMI, CAEP. Ebola Critical Care Guidelines. 2014:1–62. Available at: http://cccsnew.businesscatalyst.com/website/Guidelines/Ebola%20Clinical%20Care%20Guidelines-2014-10-28.pdf. Accessed October 28, 2014.
- 9. *Ebola Virus Disease Directive #1*. Ministry of Health and Long-Term Care of Ontario Available at: http://www.health.gov.on.ca/en/public/programs/emu/ebola/. Accessed October 31, 2014.
- 10. Interim Guidance Ebola Virus Disease: Infection Prevention and Control Measures for Borders, Healthcare Settings and Self-Monitoring at Home. Public Health Agency of Canada Available at: http://www.phac-aspc.gc.ca/id-mi/vhf-

fvh/ebola-ipc-pci-eng.php. Accessed November 7, 2014.

- 11. Guidance on Personal Protective Equipment to Be Used by Healthcare Workers During Management of Patients with Ebola Virus Disease in U.S. Hospitals, Including Procedures for Putting on (Donning) and Removing (Doffing). Center for Disease Control and Prevention Available at: http://www.cdc.gov/vhf/ebola/hcp/procedures-for-ppe.html. Accessed October 29, 2014.
- 12. Infection Prevention and Control Recommendations for Hospitalized Patients with Known or Suspected Ebola Virus Disease in U.S. Hospitals. Center for Disease Control and Prevention Available at: http://www.cdc.gov/vhf/ebola/hcp/infection-prevention-and-control-recommendations.html. Accessed October 29, 2014.
- 13. Department of Health and Human Services (HHS) Centers for Disase Control and Prevention (CDC). Interim U.S. Guidance for Monitoring and Movement of Persons with Potential Ebola Virus Exposure. 2014:1–10.
- 14. Recommendations for Safely Performing Acute Hemodialysis in Patients with Ebola Virus Disease in U.S. Hospitals. Center for Disease Control and Prevention Available at: http://www.cdc.gov/vhf/ebola/hcp/guidance-dialysis.html. Accessed October 24, 2014.
- 15. Interim Guidance for Specimen Collection, Transport, Testing, and Submission for Persons Under Investigation for Ebola Virus Disease in the United States. Center for Disease Control and Prevention Available at: http://www.cdc.gov/vhf/ebola/hcp/interim-guidance-specimen-collection-submission-patients-suspected-infection-ebola.html. Accessed October 21, 2014.
- 16. Considerations for Discharging Persons Under Investigation (PUI) for Ebola Virus Disease (Ebola). Center for Disease Control and Prevention Available at: http://www.cdc.gov/vhf/ebola/hcp/considerations-discharging-pui.html. Accessed November 7, 2014.
- 17. Safe Management of Patients with Ebola Virus Disease (EVD) in U.S. Hospitals. Center for Disease Control and Prevention Available at: http://www.cdc.gov/vhf/ebola/hcp/patient-management-us-hospitals.html. Accessed October 24, 2014.
- 18. Public Health Management of Cases and Contacts of Human Illness Associated with Ebola Virus Disease (EVD). Public Health Agency of Canada Available at: http://www.phac-aspc.gc.ca/id-mi/vhf-fvh/cases-contacts-cas-eng.php. Accessed November 7, 2014.
- 19. *Interim Guidance for Environmental Infection Control in Hospitals for Ebola Virus*. Center for Disease Control and Prevention Available at: http://www.cdc.gov/vhf/ebola/hcp/environmental-infection-control-in-hospitals.html. Accessed

November 5, 2014.

20. *Guidance for Safe Handling of Human Remains of Ebola Patients in U. S. Hospitals and Mortuaries.* Center for Disease Control and Prevention Available at: http://www.cdc.gov/vhf/ebola/hcp/guidance-safe-handling-human-remains-ebola-patients-us-hospitals-mortuaries.html. Accessed November 7, 2014.